key: cord-0007012-hp1vmgbm
authors: nan
title: Frühjahrstagung 2007 der Österreichischen Gesellschaft für Hämatologie und Onkologie
date: 2007-04-01
journal: Wien Med Wochenschr
DOI: 10.1007/s10354-007-0396-8
sha: c54fa1c9dc9bbf2d4537640919d105f2999da92e
doc_id: 7012
cord_uid: hp1vmgbm

nan

(CI): [3.7-23.3], p < 0.001) and increased after adjustment for factor V Leiden, prothrombin G20210A variant, elevated factor VIII level, hyperhomocysteinemia and BMI (OR = 11. 1, .0], p < 0.001). Carriers of the SELP Pro715 were more prevalent among controls than patients (21.7% versus 14.7%), however, the difference was statistically not significant (p = 0.19). The subgroup of carriers of the SELP Pro715 (n = 45) had significantly lower sP-selectin levels than non-carriers (31.31 ± 7.94 vs. 44.10 ± 14.08, p < 0.001).

Conclusions: Our study shows a highly significant association between elevated sP-selectin levels and VTE. Furthermore, sP-selectin levels correlate with genotype status and individuals carrying the SELP Pro715 have lower levels of sPselectin. Background: Cancer patients are at increased risk of venous thromboembolism (VTE), laboratory parameters with predictive value could help to assign a patient to a high or low risk group. We aimed to assess high platelet count as thrombosis risk predictor.

Methods: CATS is an ongoing prospective observational study in patients with newly diagnosed cancer or progression of disease, enrolment started 10/2003. Occurrence of VTE and information on the patients' anti-cancer-treatment within the follow up period are recorded. VTE has always been confirmed by imaging. Observation ends with occurrence of VTE, death or after 2 years. Kaplan Meier and Cox regression analysis were applied for statistical calculation.

Results: We included 489 patients (243 female/246 male, median age 63 yrs) with solid tumours. Main tumour entities were malignancies of the breast, lung, upper and lower gastrointestinal tract, pancreas and prostate. Distant metastases were found in 256 patients at recruitment. During the observation period VTE occurred in 27 patients (13 female/14 male, median age 62 yrs). The cumulative probability of VTE was 6.2 % after one year. High platelet count (above 459 G/l = 95 th percentile) [HR: 4.9, 95% CI 1.9-12.4], surgery [HR: 6.8, 95% CI 2.6-17.9] and radiotherapy [HR: 3.2, 95% CI 1.2-8.4] were statistically significant risk factors for VTE in multivariate analysis including platelet count, age, sex, distant metastases, surgery, chemotherapy and radiotherapy.

Conclusions: High platelet count is a clinically important independent predictive parameter for VTE in cancer patients.

Global gene expression analysis of chronic lymphocytic leukemia cells treated with arsenic trioxide F. Hamacher 1 , C. Heyder 1 , M. Scheideler 2 , I. Tinhofer 1 , Z. Trajanoski 2 , O. Merkel 1 , R. Greil 1 1 Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department for Hematology, Oncology, Hemostaseology, Rheumatology and Infectiology, St. Johannspital, Salzburg, Austria; 2 Institiute for Genomics and Bioinformatics, University of Technology, Graz, Austria Background: Gene array technology was used to shed light on the gene expression response to arsenic trioxide before and during onset of apoptosis. Arsenic trioxide effectively induces apoptosis in BCLL cells and shows selectivity for leukemic B-cells in respect to T-cells and normal B-cells of healthy age matched controls. The reason for this specificity profile is currently unknown but we believe that it is intricately linked to enzymes involved in the redox homeostasis of the cell.

Methods: B-CLL cells of 6 different patients were treated with 4 µM As 2 O 3 for 4h, 6h and 18h. 20 µg of total RNA was collected, reverse transcribed and labelled with Alexa Fluor chromophores 555 and 647. Hybridizations were carried out 16h at 42°C on a chip that contained 27 000 features. DNA Chips were scanned using an Axon Instruments GenePix ® 4100A. Data analysis was performed using GenePix ® Pro 6.0 and Acuity 4.0 Software. Cell viability and apoptosis induction of B-CLL cells was assessed by Annexin V-FITC (Alexis Pharmaceuticals) and 7-AAD staining (Beckman-Coulter).

Results and conclusions: Of almost 5000 detected expressed genes 149 or 3% were differentially expressed (73 genes upregulated, 76 genes downregulated) in early apoptotic phase after 4 and 6 hours. Not surprisingly, heat shock proteins and metallothionein were among the strongest upregulated genes. A striking number of RNAs coding for ribosomal proteins was downregulated especially after 18h reflecting a massive inhibition of the translational machinery during apoptosis. Additionally, the downregulation of mitochondrial NADH dehydrogenase and cytochrome oxidase I indicated an active downregulation of mitochondrial respiration during late apoptotic phase. Among the most downregulated genes we found the adhesion molecule CD24 and the B-cell marker CD79b which code for proteins enhancing the metastatic potential of malignant cells and a marker for trisomy 12 in CLL, respectively. Interestingly, many genes counteracting oxidative stress like thioredoxin reductase, glutathione reductase, peroxiredoxin 1, superoxide dismutase 1+2 and heme oxygenase were upregulated in all patients tested. The high number of upregulated redox relevant genes stresses the importance of oxygen radicals in arsenic trioxide mediated apoptosis in BCLL cells. We believe that the molecular mechanism making cells susceptible to As 2 O 3 can be targeted also by other substances interfering with radical detoxification. In search for such a substance which has synergistic effects with As 2 O 3 a library of 1500 compounds is currently screened. Background: Heat Shock Protein 32 (Hsp32), also known as Heme Oxygenase 1 (HO-1), has recently been identified as a stress-related survival molecule that acts anti-apoptotic and cytoprotective in inflammatory reactions. Recent data suggest that Hsp32 is also expressed in neoplastic cells in various malignancies.

Methods and results: In the present study, we provide evidence that Hsp32 is constitutively expressed in primary leukemic cells in patients with acute myeloid leukemia (AML, n = 17) and in various AML cell lines such as HL60, KG1, KG1a, and U937. Expression of Hsp32 mRNA was demonstrable by RT-PCR, and the Hsp32 protein by immunocytochemistry and Western blotting. In addition, we were able to demonstrate expression of Hsp32 mRNA and of Hsp32 protein in the CD34+/CD38-progenitor/stem cell fraction in the leukemic clone in patients with AML. The Hsp32-inducing compound hemin (10 µM) was found to promote expression of Hsp32 in AML cells. Incubation with the Hsp32-targeting drugs pegylated zink protoporphyrin (PEG-ZnPP) or styrene maleic acid-conjugated ZnPP (SMA-ZnPP), resulted in a dosedependent inhibition of growth of leukemic cells at pharmacologic concentrations (IC 50 : 5-30 µM for cell lines and primary AML cells). The SMA-ZnPP-induced growth-inhibition of AML cells were found to be associated with induction of apoptosis as evidenced by light microscopy, electron microscopy, and by a Tunel assay. In consecutive experiments, combination experiments were performed using SMA-ZnPP and AML cell lines. In these experiments, SMA-ZnPP was found to synergize with cytarabine in producing growth inhibition in all AML cell lines tested.

Conclusions: Hsp32 is a novel survival factor and interesting target in AML. The clinical significance of this observation remains to be determined in forthcoming trials. NOTCH2 is implicated in the development/homeostasis of murine Cd5+ B1 B-cells, suggesting a potential function for human NOTCH2 in B-CLL leukemogenesis. Here we show that freshly isolated B-CLL lymphocytes (n = 30) express an activated form of NOTCH2 (N2IC) irrespective of their prognostic marker profile (ie. IgVH mutational status, CD38 expression, cytogenetics). Although the majority of cultured B-CLL samples downregulate their NOTCH2 activity within one day (24 out of 30), DNA-bound N2IC complexes could be maintained by the phorbol esther TPA (1 ng/ml) accompained by an upregulation of the NOTCH2 target gene CD23 and increased cell viability. These effects are sensitive to the PKC-d inhibitor Rottlerin. The PMA induced NOTCH2 activity was found to be resistant to the γ-secretase inhibitors (GSI) DAPT and compound E in 24 out of 30 B-CLL cases suggesting that the vast majority of B-CLL cases express an activated form of N2IC which is not tethered to the plasma membrane and, thus, does not require γ-secretase for signaling. NOTCH2 inhibition either by DAPT in a GSI sensitive B-CLL case or by siRNA mediated NOTCH2 gene silencing suggests a functional relation between NOTCH2 dependent CD23 expression and B-CLL cell viability. Retrovirally transduced N2IC rescues BL41-cells from B-cell receptor (BCR) mediated apoptosis, a mechanism thought to prevent the uncontrolled expansion of CD5 + B-cells. Thus, deregulated NOTCH2 signaling seems to be a common phenomenon in B-CLL and might be critically involved in the maintenance of their malignant phenotype.

Response to fulvestrant treatment is independent of HER2 receptor status Background: In advanced breast cancer, response to endocrine therapy is usually believed to depend on certain tumour characteristics, namely HER2, estrogen receptor (ER) and progesterone receptor (PR) status, grading, and proliferation rate. These facts are well established for tamoxifen. Further, a recent trial provided data showing better outcome in HER2 positive patients when treated with a combination of anastrozole and trastuzumab as compared to anastrozole alone. In the here presented study, we evaluated whether the same factors could potentially also predict response to fulvestrant.

Methods: A total of hundred-fifty-five patients with metastatic breast cancer were included. Patients received fulvestrant at a dose of 250 mg by intramuscular injection every four weeks. Response was evaluated every three months (m) using UICC criteria. Time to progression (TTP) and overall survival (OS) were estimated using the Kaplan-Meier product limit method. A multivariate analysis (Cox regression model) was performed to evaluate factors potentially influencing treatment response.

Results: We observed a partial response in 19 pts (12.3%), SD ≥ 6 m in 56 pts (36.1%), SD > 3 m < 6 m in 7 (4.5%) and PD in 73 pts (47.1%), respectively. Median TTP was 5 m, range 2-34, CI (95%) 3.90-6.10, and median overall survival 27 m, range 3-58+, CI (95%) 22.77-31.23. A clinical benefit (CR+PR+SD > 6 months) was significantly associated with low proliferation rate (p = 0.015), non-visceral metastatic sites (p = 0.023) and fulvestrant as first line treatment (0.023).

Conclusions: As demonstrated, probability of achieving clinical benefit was independent of HER2 status. This is contradicting existing evidence from trials with other endocrine agents and might be explained by fulvestrant's unique mechanism of action: Fulvestrant blocks nuclear, cytoplasmatic and membrane bound ER. Therefore it appears to inhibit the crosstalk between growth factor receptors and the ER (which is responsible for endocrine resistance in HER2 positive disease) in a more effective manner. Methods: To investigate these issues in HLA-identical sibling peripheral blood stem cell transplantation (PBSCT), 43 consecutive transplants for haematological malignancies were retrospectively analyzed. Twenty-four patients underwent myeloablative conditioning and 19 patients received busulfan/fludarabine-based reduced intensity conditioning (RIC) .

Results: In patients with acute myelogenous leukaemia (AML) or myelodysplastic syndrome (MDS) (n = 18), regardless of conditioning type, no relapse occurred following transplants meeting both, a high (above median) natural killer (NK) cell count and missing KIR ligand, compared to all other AML/MDS patients (0% vs. 44%; p = 0.049). Quantitative graft composition was found to have significant impact exclusively in RIC transplants. Here, a trend towards reduced relapse incidence was found in patients receiving high numbers of NK cells (p = 0.09). Overall survival (OS) was superior in recipients of high T cell numbers (p = 0.01). Nonrelapse mortality (NRM) was significantly reduced in patients receiving high T cell numbers (p = 0.046). Multivariate analysis, including KIR-ligand matching, showed the probability of relapse to be significantly decreased only in patients receiving high NK cell numbers (p = 0.039).

Conclusions: These data suggest that both, the number of transplanted NK cells, and their KIR genotype in relation to the given HLA-type, play a role in the graft-versus-malignancy effect in HLA-identical PBSCT. Quantitative graft composition influenced outcome only in RIC transplants, while missing KIR ligand(s) improved the relapse incidence particularly in AML and MDS patients.

The MDM2 SNP309 genotype and the p53 status of patients interact with treatment-free and overall survival in B-CLL I. Gryshchenko 1 , M. Stoecher 1 , P. T. Daniel 2 , S. Hofbauer 1 , M. Steurer 3 , R. Greil 1 , I. Tinhofer 1 Background: Loss of function of the tumor suppressor p53 by mutation and/or deletion can result in tumorigenesis. Deletion of p53 (del17p) can be detected in 5-15% of untreated cases with B-chronic lymphocytic leukemia (B-CLL) and represents a negative prognostic factor of disease progression and therapy failure. The MDM2 gene encodes a negative regulator of p53. Recently, a single nucleotide polymorphism (SNP) in the intronic promoter region of the MDM2 gene (a T to G exchange at nucleotide 309) has been reported to increase expression levels of MDM2 leading to attenuated function of p53, and linked to the observed higher incidence of tumors in carriers with the homozygous G/G or heterozygous T/G genotype, respectively. We therefore investigated whether the MDM2 SNP309 genotype is also associated with onset or course of disease in B-CLL. Furthermore, its interaction with p53 and the in vitro sensitivity to drug-induced apoptosis was evaluated.

Methods: The MDM2 SNP309 genotype was assessed by PCR in 140 consecutive, unselected B-CLL patients who were also characterized for the p53 deletion/mutation status using interphase FISH or SSCP analysis, respectively. Using the Kaplan-Meier method and the log-rank test the relationship of the SNP309 genotype with disease-specific treatment-free and overall survival was determined. The sensitivity of B-CLL cells to apoptosis induced by fludarabine or nutlin, a specific inhibitor of MDM2, was measured by flow cytometry. Significant differences in sensitivity to apoptosis depending on the SNP309 genotypes were determined using a factorial ANOVA unpaired t-test.

Result: We did not find an association of the MDM2 SNP309 genotype with onset or incidence of B-CLL. However, a negative and gene dosage-dependent effect of SNP309 on treatment-free (T/T vs. G/G: RR 4.6, 95% CI 1.9 to 10.9, p = .0006; T/T vs. T/G: RR 1.6, 95% CI 0.9 to 2.9, p = .1) and overall survival (T/T vs. G/G: RR 7.3, 95% CI 1.6 to 33.4, p = .01; T/T vs. T/G: RR 3.1, 95% CI 0.9 to 9.9, p = .06) was observed. The gene dosage-dependent effect of the SNP309 genotype on treatment-free survival was depending of the p53 status. In cases of wt p53, the homozygous (G/G) (p = .0007) but not heterozygous (G/T) SNP309 variant (p = .65) negatively interacted with treatment-free survival. Cases with monoallelic loss of p53 (del17p) both the homo-and hetero-zygous SNP309 genotype significantly reduced treatment-free survival (p = .006).While being more resistant to fludarabineinduced apoptosis B-CLL cells from carriers with the SNP309 T/G and G/G genotype were more sensitive to nutlin-induced apoptosis in vitro (p = .03).

Conclusions: We identified the MDM2 SNP309 as an additional mechanism for inactivation of p53 in B-CLL which negatively impacts on the clinical course of B-CLL and response to cytotoxic treatment. Regimens including inhibitors of p53/MDM2 interaction might therefore represent a promising therapeutic approach for this patient cohort.

NPM-ALK fusion tyrosine kinase of anaplastic large cell lymphoma promotes neoplasia by inducing JunB via ERK1/2 and mTOR signalling Background: The nucleophosmin-anaplastic lymphoma kinase fusion protein (NPM-ALK) which is the product of the balanced chromosomal rearrangement t(2;5)(p23;q35) occurs in about half of nodal anaplastic large cell lymphoma (ALCL). ALCLs are highly proliferating tumours and usually express the AP-1 transcription factor JunB.

Methods and results: Here we report increased activity of JunB in NPM-ALK positive compared to NPM-ALK negative ALCL cells. Transcriptional regulation of JunB via the extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) pathway appears to be similar in NPM-ALK positive and NPM-ALK negative ALCL. However, activation of the mTOR pathway is restricted to NPM-ALK positive lymphomas. Inhibition of mTOR signalling in NPM-ALK positive cells decreases proliferation and downregulates JunB protein levels by shifting JUNB mRNA translation from large polysomes to monosomes and ribo-nucleic particles (RNPs). Moreover specific down-modulation of JUNB mRNA using small hairpin (sh) RNA impairs cellular proliferation by arresting the cell cycle in G1 phase.

Conclusions: Our findings reveal that the transcription factor JunB is a critical target of mTOR and is translationally deregulated in NPM-ALK positive lymphomas. In conjunction with NPM-ALK, JunB mediates cell cycle progression and may therefore represent a putative therapeutic target. This is the first study to demonstrate translational control of an AP-1 transcription factor in human neoplasia which might indicate a new paradigm of cancer biology. Methods: In this study, serum tryptase levels were determined by a fluoroenzyme-immunoassay in 165 healthy subjects, in 925 patients (pts) with hematologic malignancies (myeloproliferative disorders, MPD, n = 150; myelodysplastic syndromes, MDS, n = 233; acute myeloid leukemia, AML, n = 317; acute lymphatic leukemia, ALL, n = 26, Non Hodgkin's lymphomas, NHL, n = 30; systemic mastocytosis, SM, n = 89), and in a large cohort of control cases (pregnant women, n = 11; hepathopathy, n = 7; renal failure, n = 18; helminth infections, n = 29; reactive leukocytosis/thrombocytosis or idiopathic cytopenia, n = 115). In healthy subjects, the 95%percentile ranged between 2.4 and 9.5 ng/ml (median 5.7 ng/ml).

Results: Healthy controls aged ≤16 years had a slightly lower median serum tryptase level compared to older control subjects (p = 0.03). Among pts with non hematologic disorders, slightly elevated serum tryptase levels (up to 24 ng/ml) were detectable in 6/18 pts with severe renal failure and in 3/29 pts with helminth infections. When analyzing hematologic malignancies, tryptase levels >15 ng/ml could be detected in pts with myeloid neoplasms exclusively, whereas in most pts with lymphoproliferative disorders, tryptase levels were normal. Among myeloid neoplasms, elevated tryptase levels were recorded in 83% of the pts with SM, 36% of pts with AML, 34% of the pts with CML, and 29% of the pts with MDS. The highest tryptase levels, sometimes exceeding 1000 ng/ml, were found in pts with SM or AML-M4eo. In pts with CML, elevated tryptase levels were found to be associated with an unfavorable prognosis concerning survival (survival in CML pts with tryptase <15 ng/ml: 100% vs. 71% in those with >15 ng/ml, after 60 months, p < 0.007). In most pts with AML, SM, or CML, the initially enhanced serum tryptase levels decreased in response to successful cytoreductive or targeted therapy. In pts with AML, a persistently elevated serum tryptase in complete hematologic remission (CR) was found to be associated with an increased risk of relapse compared to those with normal tryptase in CR.

Conclusions: In summary, tryptase is a new and simple diagnostic marker of myeloid neoplasms. In SM, AML, and CML, tryptase is also a useful marker to monitor (minimal Freie Vorträge Hämatologie residual) disease during treatment with cytoreductive or targeted drugs. Moreover, in AML and CML, measurement of tryptase is of prognostic significance. All in all, tryptase is recommended as a new important serum-marker in clinical hematology.

Marked activity of bortezomib, rituximab, and dexamethason (BORID) in heavily pretreated patients with mantle cell lymphoma Background: Bortezomib (B) belongs to a new class of anti-cancer agents, the proteasome inhibitors, and has documented activity in multiple myeloma and mantle cell lymphoma (MCL). Preclinical studies suggest that B has synergistic activity with rituximab (R), which provides a rationale for the exploration of treatment combinations.

Aims: To evaluate the activity and safety of B in combination with R and dexamethasone (BORID) in patients with relapsed and refractory MCL (phase II trial).

Methods: A treatment cycle consists of B at 1.3 mg/m 2 administered on days 1, 4, 8, and 11 , R at 375 mg/m 2 administered on day 1, and dexamethasone 40 mg orally on days 1 to 4. Cycles are repeated every 3 weeks for a total of 6 treatment cycles. Patients (pts) with progressive MCL after at least one prior line of therapy (including CHOP or a CHOP-like regimen) are eligible.

Results: We have completed enrollment of 16 pts (median age, 67 years; range, 48 to 75 years) after a median of 3 lines of prior therapies (range, 1 to 6, prior rituximab in 88%; thalidomide in 50%; high-dose therapy in 31%; a fludarabinecontaining regimen in 31%). Median time between start of frontline therapy and study inclusion was 42 months (range, 11 to 98 months). Severe adverse events (>grade II) included infections (herpes zoster in 2 pts, bacterial pneumonia, mucosal candidiasis), peripheral neuropathy (3 pts), fatigue (2 pts) and vasculitic skin infiltrates in 3 pts. Thrombopenia (<50 G/L) occured in 2 pts. All adverse events were managable by standard means of supportive care and prolongation of the treatment interval between cycles. Of 15 pts evaluable for efficacy, 11 have achieved a response (5 CR, 6 PR), and 2 pts experienced stable disease. Pts in CR were also negative for disease activity by PET scanning (4 pts tested to date). Skin infiltrates (histologically proven T-cell infiltrates) preceded achievement of CR in 2 pts. Remission status appeared to be associated with progression-free survival (PFS): Patients in CR had longer PFS (22+, 17+, 12+, 12, and 4+ months) compared to patients in PR (15, 11, 6+, 6, and 6 months) .

Conclusions: BORID has promising activitiy and managable toxicity in patients with heavily pretreated MCL. Achievement of a CR appears to be an important factor for sustained disease control, and development of a vasculitic rash may be an early indicator of a favorable response. Background: Treatment intensification improved outcomes in children with t(1;19)/E2A-PBX1 acute lymphoblastic leukemia (ALL). Lessons from the analysis of patients treated over the past years could help to identify treatment components essential for this ALL subtype.

Methods: We performed a retrospective analysis on a cohort of 859 consecutive Caucasian children with newly diagnosed ALL who were treated between 1986 and 2003 in Austria, and identified 33 children (3.8%) with a t(1;19)/E2A-PBX1 ALL. Demographic, diagnostic, and treatment related variables; response and survival data were analyzed.

Results: The overall survival rate of the 33 children with t(1;19)/E2A-PBX1 ALL was 91% ± 5% (95% confidence interval (CI) 81% to 100%). Median follow-up of the 30 survivors was 7.5 years (range, 3 to 14.4 years). The 5-year eventfree survival (EFS) rate was 88% ± 6% (95% CI 77% to 100%). Leukemia relapses occurred in four children with very early (2, 10, and 11 months after diagnosis) or early onset (24 months after diagnosis); and three children subsequently died from the disease. Patients treated on the ALL-BFM 86 treatment trial had a poorer outcome than those treated on later trials (ALL-BFM 86, N = 7, 5-year EFS 57% ± 19%, 95% CI 30% to 100% versus ALL-BFM 90, 95, and 2000, N = 26, 5- year EFS 96% ± 4%, 95% CI 89% to 100%) (P = 0.004).

Conclusions: These data document that treatment according to contemporary ALL-BFM protocols is highly effective in children with t(1;19)/E2A-PBX1 ALL. Implementation of early dose-intensified remission induction, as scheduled since trial ALL-BFM 90, may be an essential treatment component. Background: Central nervous system (CNS) relapse in chronic myeloid leukemia (CML) is rare, and if recorded, is usually found to occur in patients with lymphoblastic transformation. The BCR/ABL tyrosine kinase inhibitor imatinib is highly effective in CML, but hardly crosses the blood-brain barrier. During the past few years, it has been described that CNS relapses can occur in patients with CML treated with imatinib.

Methods: We report on two CML patients who developed an isolated myeloid CNS relapse during treatment with imatinib. One patient was in major cytogenetic remission at the time of CNS relapse. The myeloid origin of neoplastic cells in the cerebrospinal fluid (CSF) was demonstrated by immunophenotyping in both cases, and in both patients, the leukemic origin of cells was confirmed by detection of BCR/ABL transcripts. No BCR/ABL kinase mutations were found. Both patients received intrathecal liposomoal cytarabine (50 mg each cycle; 4 and 6 cycles, respectively). In one patient, additional CNS radiation was performed. In the other patient who developed a hematologic relapse, systemic therapy with dasatinib (2 × 70 mg per day p.o.) was started.

Results and conclusions: In response to treatment, the clinical symptoms resolved and the leukemic cells in the CSF disappeared. In aggregate, our data suggest that anatomic resistance against imatinib in the CNS can lead to a myeloid CNS relapse. Whereas liposomal cytarabine (plus radiation) may be effective as local therapy in these patients, systemic treatment with second generation BCR/ABL tyrosine kinase inhibitors crossing the blood brain barrier has to be considered as long term treatment approach. In addition, such novel drugs have to be discussed as prophylactic therapy.

Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining cobalt alkyne complexes with the tyrosine kinase inhibitor imatinib I. Ott 1 , A. Abraham 2 , P. Schumacher 2 , H. Shorafa 1 , G. Gastl 2 , R. Gust 1 , B. Kircher 2 Background: The tyrosine kinase inhibitor imatinib is successfully used in the treatment of chronic myeloid leukemia, but the occurrence of resistance phenomena can significantly limit its therapeutic impact. Imatinib shows synergistic effects with cisplatin, suggesting that the combination with classical cytostatics can enhance its antineoplastic activity. Other non-cytostatic drugs have been shown to exert antitumoral activity when combined with conventional chemotherapeutics. These include nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin. Recently, we reported on cobalt alkyne complexes as a new class of anti-tumor agents. The most active derivative Co-ASS is the hexacarbonyldicobalt complex of 2-acetoxy-(2-propynyl)benzoate, an ester of aspirin.

Methods: The present study evaluated the combined effects of cobalt alkyne compounds containing propargylic acid esters with imatinib on human acute and chronic myeloid leukemia cell lines.

Results: The cell growth inhibitory and proapoptotic activities achieved with these single agents were moderate. However, cobalt complexes combined with imatinib at subop-timal concentrations showed an additive or synergistic antiproliferative effect. In fact, maximum cell growth inhibition and apoptosis was obtained with complexes containing ligands derived from the NSAIDs aspirin and naproxene.

Conclusions: Cobalt alkyne complexes based on the classical NSAIDs aspirin and naproxene showed higher antiproliferative and proapoptotic activities than the parent NSAIDs and proved to be synergistic activity with imatinib. These data suggest that CML patients under imatinib treatment might benefit from coadministration of cobalt-modified NSAIDs.

Arsenic trioxide induces apoptosis preferentially in B-CLL cells from high risk patients including del17p13 Background: 1) Assess the in vitro toxicity of arsenic trioxide on B-CLL cells in correlation to prognostic factors, including del17p, IgVH, ZAP-70, and CD38 2) Test the selectivity of the drug compared to normal B-cells and T-cells 3) Investigate the mechanisms by which cell death is induced.

Methods: Flow cytometry, annexin V assay, superoxide dismutase (SOD) activity assay, reactive oxygen species (ROS) measurement by dihydroethidine, p53 siRNA knockdown.

Results: As 2 O 3 shows selectivity for B-CLL cells over Tcells from B-CLL patients and preferentially kills neoplastic B-cells compared to normal B-cells of healthy age matched controls. In vitro fludarabine resistance of B-CLL cells can be overcome by As 2 O 3 . From the patient subgroups tested, B-CLL cells with 17p deletion, high expression of CD38 or high Rai stage are more susceptible to As 2 O 3 . Unmutated IgVH and high ZAP-70 expression also predisposes B-CLL cells to arsenic induced cell death, albeit only with borderline statistical significance. The cytotoxic effect of arsenic is at least partially attributed to the generation of ROS. We report here that high SOD activity is correlated to high As2O3 toxicity. Interestingly, we find a similar correlation using the specific SOD inhibitor and ROS generating agent 2-methoxyestradiol.

Conclusions: We hypothesize that upregulation of SOD activity is vital to protect B CLL cells from elevated ROS levels and induction of cell death. This corresponds with our finding that B-CLL cells from pretreated patients have higher SOD activity, presumably as a protection from higher intracellular stress levels after chemotherapy with purine analogues and alkylating agents. Background: The purpose of this study was to examine the influence of androgen receptor (AR) expression in tumor tissue on survival of patients with metastatic breast cancer.

Methods: Tumor specimens of 232 patients with metastatic breast cancer were examined for expression of AR by immunohistochemistry. AR expression was classified according to the extent of immunostaining as score 0, 1+, 2+, or 3+.

Results: AR expression (score 1+, 2+ or 3+) was observed in 164 (70.7%) tumors. The median survival after disease relapse (SAR) of patients with AR expressing tumors was significantly longer compared to that of patients with tumors not expressing AR (21.89 months, 95% CI 17.23-26.55 versus 11.99 months, 95% CI 9.36-14.62; log-rank test 0.0282). In addition, patients with AR score 3+ in the primary tumor tissue had a significantly longer disease-free survival (DFS) compared to patients with AR score 0, 1+ and 2+, (24.67 months, 95% CI 13.72-35.62 versus 16.36 months, 95% CI 13.18-19.54, log rank test 0.0043). Multivariate Cox analyses showed no statistically significant influence of AR expression on DFS or SAR.

Conclusions: SAR is significantly longer in patients with AR expressing breast cancer. However, AR expression is not an independent prognostic factor for SAR in patients with metastatic breast cancer.

Ergebnisse einer österreichweiten Karzinoid-Evaluierung -"Austrian Carcinoid Data Evaluation (ACDE)" R. Ruckser Methodik: In den Jahren 2001-2003 wurden alle Chirurgischen, Internen und Pathologischen Abteilungen österrei-chischer Spitäler eingeladen, ihre Daten über Patienten mit der Diagnose "Karzinoid" der letzten 10 Jahre unserem zentralen Auswertungsbüro zur Verfügung zu stellen.

Ergebnisse: 391 Abteilungen regierten mit Rückmeldungen. Von diesen 391 Abteilungen meldeten 144 Abteilungen (37 %) Patienten mit der Diagnose Karzinoid. 236 (63 %) der antwortenden Abteilungen hatten keine Patienten mit dieser Diagnose. Insgesamt wurden 1067 Patienten gemeldet. Das entspricht 2,7 Patienten pro Abteilung in den letzten 10 Jahren (entspricht dem Berichtszeitraum von 98 % aller Abteilungen). Es wurden exakt je 502 weibliche bzw. männliche Patienten gemeldet -63 (6 %) ohne Geschlechtsangabe. Das mediane Alter der ausgewerteten Patienten betrug 58a (Range 3-96a). Die Gesamtzahl der gemeldeten Kinder (Alter bis 16a) betrug 42 (4,3 %), davon 67 % weibliche Patienten. Die gemeldeten histologischen Daten werden bei der Tagung im Detail präsentiert. 19 % der Patienten hatten ein Foregut-Karzinoid, die Zahl der Midgut-Lokalisationen betrug 52 %, bei 13 % wurden Hindgut-Karzinoide berichtet. 295 Patienten (28 %) hatten eine Appendix-Lokalisation (davon 62 % weibliche Patienten). Bei 367 Patienten (34 %) wurden die durchgeführten Therapien berichtet. 76 % der Patienten hatten eine Operation, bei den restlichen 24 % fanden multimodale Therapiekonzepte (kombinierte Lokaltherapien + systemische Therapien, kombinierte systemische Therapien) Anwendung. Die genaue Aufschlüsselung dieser verschiedenen Therapiekonzepte wird berichtet. Von den berichteten systemischen Therapiekonzepten waren die Anwendung Somatostatin-Analoga und zytostatischen Chemotherapien die häufigsten (je 11 %). 6 % der Patienten wurden mit Interferon-alpha-Präparaten behandelt. Die unterschiedlichen Chemotherapien und Kombinationen mit Zytokinen werden im Detail präsentiert.

Schlussfolgerungen: Die Zahl dieser retrospektiv gemeldeten Patienten entsprach etwa 50-60 % der tatsächlich erwarteten Zahl an Erkrankungen im Dokumentationszeitraum. Die Ergebnisse können somit -trotz Einschränkungen -als repräsentativ betrachtet werden. In Zukunft könnte eine multizentrische prospektive zentrale Datenerfassung wesentlich die Erkenntnisse über die Erkrankungsverläufe von Patienten mit Karzinoiden vertiefen. Integrin adhesion molecules regulate many cellular behaviors, including cell migration, proliferation, differentiation and cell survival. Recently, CD98hc has been identified to mediate integrin induced signal transductions via direct CD98hc/ integrin beta cytoplasmic tail interaction. Cell adhesion is inducing integrin dependent focal adhesion kinase (FAK), src family kinases (SFK), Akt and Rho-GTPase phosphorylation and activation. Depletion of CD98hc expression or blockage of CD98hc / integrin complex formation impaired integrin induced signal transduction leading to an increase in Freie Vorträge Onkologie cell death and stop in proliferation. Furthermore, a genetic knockout of CD98hc in animals is embryonic lethal on E 3.5 to E 9.5. While cell adhesion in tumor cells is dispensable, the cytoplasmic domains of integrins have been shown to be essential to guarantee tumor cell functions. Consistently, it has been shown, that an overexpression of CD98hc in murine fibroblast show anchorage-independent growth, while a genetic knockdown in a teratocarcinoma model blocked tumor growth. In the present study we aimed to characterize the role of CD98hc in malignant diseases as a potential diagnostic and prognostic marker, as well as to identify a functional role of highly expressed CD98hc in tumorigenesis. Therefore, we screened different renal cancer types in multi tissue arrays. While CD98hc is highly expressed in papillary renal cancer and in renal cell cancer (RCC), no CD98hc could be detected in oncocytoma or chromophobe renal tumors. Interestingly, CD98hc expression directly correlated with differentiation of renal cell cancer (grading). A retrospective study we correlate CD98hc expression in 120 RCC samples with respective patient data, which gives clear insights in a potential prognostic role of CD98hc expression in this disease. These in vivo immunohistochemisty data could be confirmed in a well defined cell line, Kaci2, showing high CD98hc expression, accompanied with a high proliferative phenotype. Using different strategies to interfere with CD98hc expression, like siRNA we could analyze the functional role of this protein in tumor cell behaviors like cell survival and proliferation. From this data we conclude, that CD98hc might represent guidance for the rational use of CD98hc staining in diagnostic/ prognostic histopathology. An understanding of the mechanisms how CD98hy mediates integrin-dependent signaling could lead to novel therapeutic strategies for oncology. Background: Recent evidence suggests that the addition of trastuzumab to antracyclin-containing combination chemotherapy increase the rate of pathological complete response (pCR) in patients with locally advanced her2/neu positive breast cancer. Due to the overlapping cardiotoxicicty of trastuzumab and antracyclins there is an increased risk for cardiac side effects in the treatment of this patient population.

Methods: The aim of our study was to minimize the potential risk of cardiotoxicity by adding liposomal doxorubicin (Myocet ® ) to docetaxel and trastuzumab in the neoadjuvant treatment of patients with her2/neu positive breast cancer. Up to now, we treated 11 patients (median age 48 years; range 35-66) with a combination therapy containing liposomal doxorubicin (Myocet ® ) 60 mg/m 2 d1, docetaxel 75 mg/m 2 d1, trastuzumab 8 mg/kg (cycle 1) d1, 6 mg/kg (cycle 2-6), q3 for 6 cycles. All patients received prophylactic pegylated G-CSF as well as antiemetic treatment with 5HT3 blockers and prednisone.

Results: A total of 64 cycles were administered and, as of now, only two episodes of febrile neutropenia as well as two episodes of grade 3 neutropenia but no other grade 3 or 4 toxicities were observed. Echocardiography revealed a >10% decline in left ventricular ejection fraction (65% to 50% LVEF) in one patient all other patients showed no decline in LVEF. Five out of 10 patients evaluable for pathological response achieved a pathological complete response.

Conclusions: Neoadjuvant treatment with liposomal doxorubicin Myocet ® , docetaxel and trastuzumab is well tolerated. No severe cardiotoxicity has been observed. The high pCR rate of this regimen with its favourable side effect profile warrants further investigation.

EpCAM expression in squamous cell carcinoma of the oral cavity: frequency and relationship to clinicopathologic features K. Laimer 1 , D. Fong 2 , G. Gastl 2,3 , P. Obrist 4 , F. Kloss 1 , T. Tuli 1 , R. Gassner 1 , M. Rasse 1 , B. Norer 1 , G. Spizzo 2,3

Background: This retrospective study was designed to investigate the prognostic significance of EpCAM expression in human oral squamous cell carcinoma on a long-term follow-up.

Methods: EpCAM expression was examined immunohistochemically on a tissue microarray (TMA) of paraffin embedded tissue specimens from 77 consecutive patients who underwent surgical treatment for squamous cell carcinoma of the oral cavity in the period between 1980 and 1997 at the Department of Craniomaxillofacial and Oral Surgery, Medical University of Innsbruck.

Results: High EpCAM expression was found in 17 (22.1%) of the tumor samples. Using Kaplan-Meier analysis no correlation of EpCAM overexpression was observed with conventional clinicopathologic features in this patient cohort.

Conclusions: Taken together, these data suggest that EpCAM might become an attractive treatment target in a subgroup of patients with OSCC. Epidemiology, outcome and costs of invasive fungal infections in patients with haematological malignancies -a ten years' single centre experience J. Auberger 1 , D. Nachbaur 1 , H. Ulmer 3 , B. Nogler-Semenitz 4 , G. Gastl 1 , C. Lass-Flörl 2 Background: Invasive fungal infections (IFI) are recognised as an increasing source of life-threatening complications with high mortality in patients with haematological malignancies.

Methods: We retrospectively analysed 1095 patients who underwent treatment either with cytoreductive chemotherapy alone or subsequent allogeneic and/or autologous stem cell transplantation (HSCT) at our institution between January 1995 and December 2004 for occurrence of invasive fungal infections. Clinical and epidemiological data were collected.

Results: The cumulative incidence of invasive fungal infections among all treated patients was 15.3% (167/1095). According to the 'European Organisation for Research on Treatment of Cancer' (EORTC)/ Mycoses Study Group (MSG) criteria, IFI were classified as follows: 54/167 (32%) "proven", 70/167 (42%) "probable" and 43/167 (26%) "possible" IFI. Patients receiving an allogeneic HSCT were significantly less often classified as having "proven" IFI. Patients diagnosed with "proven" IFI and being treated with antifungal monotherapy significantly more often received treatment with (liposomal formulations of) Amphotericin B (26/147, 45%, p = 0.009), compared to patients having "probable" (18/147, 29%), or "possible" IFI (14/147, 35%). Antifungal therapy was significantly more often switched in patients with "proven" IFI (10/28, 33%) (p = 0.015), compared to patients with "probable" (15/28, 25%) or "possible" IFI (3/28, 7%). Fungus-related death significantly more frequent occurred in patients having "proven" IFI (19/22, 86%; p = 0.0), compared to patients with "probable" (3/22, 14%) or "possible" IFI Poster (0/22, 0%). Aspergillus fumigatus and terreus were the predominant cause of IFI in 151/167 cases (90%), followed by Candida species in 13/167 patients (8%). The overall mortality rate was 72.5% (121/167). Fungus related death occurred in 13% (n = 22). In univariate analysis, patients being diagnosed with "possible" IFI had a significantly better OS (3 yr OS: 100%; 95%, CI; p = 0.0) compared to "probable" (3 yr OS: 91%; 95%, CI) and "proven" IFI (3 yr OS: 53%; 95%, CI). By multivariate analysis, only being diagnosed with "proven" IFI turned out to be an independent risk factor for a dismal outcome (HR 1.67 (1.05-2.66), 95%, CI; p = 0.018). Concerning costs for antifungal monotherapy in earlier years, expenses increased approximately 13-fold from 2,250 € (70 kg patient for 30 days) for Amphotericin B to 28,800 € for therapy with "novel" drugs like lAmB. Costs for combination therapy developed in a 7-fold accretion comparing "older" Amphotericin B/ Itraconazole (6,000 €) to the most expensive "novel" pairing lAmB/ Caspofungin (42,930 €).

Conclusions: Despite important advances in modern antifungal treatment have been made cumulative incidence of invasive fungal infections in patients with haematological malignancies remains high and patients' outcome has not improved substantially. However, costs for antifungal therapy increased noticeable. Therefore, timely and preferably exact diagnosis and impetuous treatment remain the most important premises for successful treatment. Background: The use of animal-derived products during human stem cell processing bears the evident risk of xenogeneic prion, virus, or zoonose contamination. Human platelet lysate (HPL) is a rich source of cytokines and growth factors with the potential to replace fetal bovine serum (FBS) during ex vivo stem cell manipulation. In this study we compared the gene expression profile of human multipotent mesenchymal stromal/stem cells (MSC) during ex vivo expansion for clinical applications under the aegis of either FBS or HPL.

Methods: The Applied Biosystems 1700 Expression Array System was used for full genome expression profiling of MSC after a 12-14 day expansion period in a previously optimized clinical scale expansion system. Data were obtained from three independent MSC donors in a time course of three consecutive MSC propagation cycles. A starting amount of 40 µg total RNA was directly labeled and DIG-labeled cDNA was hybridized to Human Genome Survey Microarray V2.0. Attribution of regulated genes to biological processes and pathways was done using the PANTHER ® db analysis software.

Results: We identified more than 300 genes that are differentially regulated upon culture of MSC in HPL compared to FBS. Biological processes specifically activated in HPL culture include mesoderm development, cell cycle control, hema-topoiesis and angiogenesis which interestingly correspond to a considerable proportion of the regenerative function of MSC. In contrast, processes related to cell adhesion, adhesion-mediated signaling, cell structure, cell motility and cell communication are significantly upregulated in MSC after FBS in comparison to HPL culture.

Conclusions: Replacing FBS with HPL not only avoids bovine prion, viral and zoonose contamination of MSC for clinical use. The tightly regulated gene expression profiles under the aegis of human growth factors and cytokines provided by HPL may help to develop novel stem cell therapy strategies. Background: Systemic mastocytosis is a clonal myeloid disorder characterized by an abnormal accumulation and growth of mast cells and their progenitors in one or more extracutaneous organs. In most cases, the bone marrow is involved and thus is examined in suspected disease. Expression of CD25 in bone marrow mast cells, with or without coexpression of CD2, is an important minor criterion of systemic mastocytosis. So far, most studies have examined CD25 expression on mast cells by flow cytometry.

Methods: We examined the expression of CD25 by bone marrow mast cells in systemic mastocytosis (n = 25) by immunohistochemistry and compared the results with those obtained from flow cytometric assessement of CD25 expression.

Results: In the majority of all cases (23/25; 85%), CD25 was detectable by both staining techniques. In one patient, CD25 was only detectable by immunohistochemistry, but not by flow cytometry, whereas in 1 patient, in whom no compact MC infiltrates were detectable in the bone marrow, only the flow cytometric evaluation revealed aberrant expression of CD25 in mast cells.

Conclusions: CD25 immunohistochemistry is equally diagnostic and sensitive in systemic mastocytosis compared to flow cytometry and thus can be recommended as diagnostic test to document the phenotype-related minor SM criterion. Our data also suggest, however, that optimal assessment of CD25 expression in neoplastic MC in all patients requires the application of both techniques, i.e. immunohistochemistry and flow cytometry.

Universitätsklinik für Mund-, Kiefer-und Gesichtschirurgie, Paracelsus Medizinische Privatuniversität, Salzburg, Österreich Grundlagen: Die oralen Nebenwirkungen einer systemischen Chemotherapie können sich massiv auf die Lebensqualität eines Patienten auswirken. In dieser Übersicht sollen die wichtigsten Beeinträchtigungen und deren Behandlung dargelegt werden.

Methodik: Aus dem Krankengut der Universitätsklinik für Mund-, Kiefer-und Gesichtschirurgie der PMU in Salzburg werden Beispiele für Schäden an Zähnen, Mundschleimhaut, Speicheldrüsen und Kieferknochen demonstriert und Hinweise für Behandlung und Prophylaxe gegeben.

Ergebnisse: Zähne sind vor allem durch die Vernachlässigung der Mundhygiene infolge von Schmerzen bei Mucositis gefährdet; auch mehrfaches Erbrechen kann zu Schmelzschäden führen. Eine schwere orale Mucositis kann bis zur Unmöglichkeit der Nahrungsaufnahme und des Tragens von Prothesen gehen, sodass die Chemotherapie unterbrochen werden muss und u. U. eine Ernährungssonde erforderlich ist. Nach Zahnextraktionen können schwere Blutungen oder eine Osteomyelitis des Kieferknochens auftreten. Eine Verringerung des Speichelflusses und des Geschmackssinns vermindert gleichfalls die Lebensqualität.

Schlussfolgerungen: Sobald die Indikation zu einer systemischen Chemotherapie gegeben ist, sollte der Patient einem Zahnarzt vorgestellt werden, damit die wichtigsten prophylaktischen Maßnahmen (Extraktionen, Füllungen, Wurzelbehandlungen, Kontrolle von Implantaten oder Prothesen, Unterweisung in exakter Mundhygiene) getroffen werden können. Bei zahnärztlichen Problemen während einer Chemotherapie sollen Eingriffe möglichst vermieden oder nur unter großer Vorsicht (stat. Aufnahme, AB) durchgeführt werden. Erst nach vollständiger Normalisierung der Blutwerte können zahnärztliche Behandlungen wieder ohne besondere Kautelen erfolgen. 20 Jahre Langzeitüberleben ist für einzelne Patienten mit kleinzelligem Bronchialkarzinom möglich U. Benold 1 , S. Polleres 2 , E. Ulsperger 1,2 , K. Geissler 1,2 1 5. Medizinische Abteilung, Onkologie, 2 Ludwig Boltzmann Institut für klinische Onkologie, Krankenhaus Hietzing, Wien, Österreich Grundlagen: Das mediane Überleben von Patienten mit kleinzelligen Bronchialkarzinomen (SCLC) im so genannten Frühstadium (limited disease -LD) beträgt 12-20 Monate, im fortgeschrittenen Stadium (extensive disease -ED) 7-11 Monate. Die 5-Jahres-Überlebensrate wird, je nach Autor, bei LD mit etwa 10 % und bei ED mit knapp über 0 % angegeben. In der überwiegenden Mehrzahl der Therapiestandards wird die primäre Chemotherapie gefolgt von Strahlentherapie als optimale Behandlungsmethode angeführt.

Methodik: Nach Auswertung unserer Tumordatenbank für Patienten mit SCLC fanden sich 385 Patienten mit der Diagnose "Neuroendokriner Tumor Grad III" (NEC III). Die histologischen Diagnosen von 23 erfassten Patienten zeigten kein klassisches SCLC (NEC III), sondern neuroendokrine Pankreas-, Prostata-, Merkelzell-, Ovarial-, Mammakarzinome, Thymome oder typische Karzinoide. Mit der Zielsetzung, therapeutische Charakteristika oder Selektionsfaktoren für Langzeitüberlebende zu finden, unterzogen wir alle Patienten mit (NEC III) der Lunge, SCLC, die länger als 2 Jahre nach Diagnose lebten, einer retrospektiven Analyse.

Ergebnisse: Von den 362 SCLC-Patienten leben in unserem Kollektiv 62 Patienten (17,1 %) über 24 (25-243) Monate. Unter diesen befinden sich 8 Patienten mit Mehrfachtumoren. 22 Patienten wurden operiert, wobei nur 4 eine neoadjuvante Chemotherapie erhielten und 18 primär reseziert wurden. 8 dieser Patienten leben derzeit zwischen 57 und 243 Monate nach kombinierter Operation, Chemo-und Strahlentherapie. 40 Patienten mit NEC III erhielten Chemotherapie gefolgt von Irradiatio. Überraschend fanden sich in dieser Gruppe 6 Patienten mit bei der Diagnose verifizierten Fernmetastasen (ED), während 34 Patienten eine typische LD aufwiesen. Hinsichtlich der verabreichten zytostatischen Therapieschemata konnte kein eindeutiger Trend abgelesen werden, doch war bei 29 der 40 Patienten in der Induktionstherapie Vepesid enthalten, aber nur bei 10 Cisplatin und bei 6 Patienten Carboplatin.

Schlussfolgerungen: Die unterschiedlich verwendeten Chemotherapieschemata erlaubten keinen Rückschluss auf die Dauer des Überlebens. Patienten mit im Staging operablen Bronchuskarzinomen sollen primär nicht aufgrund der Histologie (im Falle eines SCLC) von einer Operation ausgeschlossen werden. Konsequent durchgeführte, kombinierte Behandlungsstrategien können beim einzelnen Patienten zur Heilung führen. Background: Mantel cell lymphoma (MCL) is an aggressive B-cell lymphoma which is characterised by early dissemination and unfavourable clinical course. The implementation of autologous stem cell transplantation (mid 1990s) extended the therapeutic options for this poor-risk subtype. Particularly the intensification of the chemotherapeutic regimen and the combination with the monoclonal antibody Rituximab led to sustained disease control. We evaluated the efficacy of an intensified immunochemotherapy combined with high-dose therapy (HDT) and autologous stem cell rescue (ASCT) in patients with mantle cell lymphoma.

Methods: Since 1995 14 out of 25 consecutive patients with newly diagnosed or pre-treated MCL of stage III-IV were eligible for HDT followed by autologous stem cell transplantation. Exclusion criteria for the remaining 11 patients were age over 70 (6), resistance to chemotherapy (2), severe comor-bidity (apoplexia [1] , chronic atrial fibrillation [1] ) and recurrent infectious complications (tuberculosis [1] ). Induction therapy consisted of Rituximab (375 mg/m²; d1) plus CHOP-21 for 4-6 cycles followed by intensification (and priming) chemotherapy for 2 to 3 cycles of CLAEG (3 days Cladribine 0,2 mg/kg, ARA-C 1,5 g/m², Etoposid 60 mg/m²) and on day 1 Daunoxome 80 mg/m² or Idarubicine 8 mg/m². Autologous stem cell transplantation was performed at a median of 9 (7-13) months from diagnosis with 11 primary patients and 3 patients in relapsed disease status. In addition to high dose conditioning chemotherapy (BEAM) 4 doses of Rituximab (d -9, -1, +48 and +55) were administered.

Results: Fourteen Patients (6 female, 8 male) at a median age of 57 (49-66) years were treated. 5 reached CR, 4 VGPR and 5 PR before receiving ASCT. In 4 patients Rituximab at day +48 and +55 was cancelled due to complications such as pneumonia (2), herpes zoster (1) or exanthema (recurrent folliculitis/ erythema like lesions) (1) . A median number of 5.64 × 10ˆ6 /kg CD 34 positive cells (1.65-29.5 ) were reinfused. The engraftment was generally prompt and durable (granulocytes >0.5 G/l day +10 (9-11), platelets >50 G/l day +14 (10-17)). Only in one case (male patient, age at TX: 55 years) a delayed regeneration (d +140; granulocytes >0.5 G/l +11, platelets day +21) was observed. Side effects of transplantation were mucositis grade I-II in 12 patients, 4 suffered from emesis grade II-III and 4 from enteritis grade I-II. Fever of unknown origin occurred in 4, septicaemia in 2 and pneumonia in 2. Grade 4 toxicities and treatment related deaths were not observed. Following transplantation all patients reached clinical and molecular CR. 12 patients are still in CCR with a median observation period of 33 months (5-58). 2 patients relapsed after 17 and 26 months and died 58 and 34 months after transplantation. As late infectious complications 3 patients developed pneumonia and 3 herpes zoster. A propagation of erythema migrans and sarcoidosis was seen in 1 patient each.

Conclusions: R-CHOP intensified by high dose treatment (CLAEG-D or CLAEG-Ida) including ASCT using BEAM regimen and Rituximab is accompanied by acceptable toxicity and improves outcome of patients with MCL, allowing long-term disease control.

Lymphoid microenvironment inhibits apoptosis in B-CLL cells through the activation of PI3-K/Akt pathway D. Demirtas 1 , S. Schnabl 1 , M. Hilgarth 1 , R. Hubmann 1 , J. D. Schwarzmeier 1,2 , U. Jaeger 1 , M. Shehata 1,2 B-cells in chronic lymphocytic leukemia (B-CLL) is a disease of accumulation of clonal B cells which could be due to inhibition of apoptosis and long survival of the leukemic cells. This could be due to the activation of anti-apoptotic cascades through interaction with the lymphoid microenvironment. The aim of this study was to elucidate the role of lymph-oid microenvironment in activation of the potent anti-apoptotic PI3-K/Akt signal transduction pathway and prolongation of survival of B-CLL cells. Stromal fibroblasts of bone marrow (BMFs) were used as an in vitro model for lymphoid microenvironment and to test their ability to inhibit spontaneous apoptosis of B-CLL. Co-cultivation of B-CLL cells with human BMFs significantly inhibited apoptosis of B-CLL cells. Trans-well culture experiments indicated that the supportive effect is provided by cell-cell contact and soluble mediators produced by viable fibroblasts. To explore the involvement of PI3-K/Akt pathway in the anti-apoptotic effect of stromal fibroblasts, co-cultures were performed in presence of PI3-K inhibitors (wortmannin or LY294002) or siRNAs against PI3-K (p110 subunit) and Akt1. These inhibitors significantly reduced the supportive effect of stromal fibroblasts and induced apoptosis in B-CLL cells. Induction of apoptosis was associated with a significant decrease in the intracellular PIP3, PI3-K, PDK1 and Akt1, NF-kappa B, IKK, and de-phosphorylation/activation of tumour suppressor protein PTEN. Studies using phosphospecific anti-PTEN antibody demonstrated that PBMC of CLL patients (n = 40) highly express a phosphorylated (inactive) form of PTEN. The results demonstrate that PI3-K/Akt pathway is involved in inhibition of apoptosis of B-CLL cells and suggest that interaction of the leukemic cells with lymphoid microenvironment maintains the activation of this pathway. The data also suggest that targeting this pathway represents a new therapeutic approach in B-CLL. Background: B-cell chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the western world and is characterized as a monoclonal disorder with a progressive accumulation of functionally incompetent lymphocytes. The search for tumorigenic stem cells in hematopoietic neoplasias has been initiated decades before and cells sharing stem-cell properties have been identified in acute and chronic myeloid leukemia (AML, CML) and several solid tumors. Striking parallels can be found between cancer cells and stem cells regarding their capacity for long-term self-renewal. Signaling cascades such as the Wnt-, Sonic Hedgehog-, and Notch-pathway have been described to regulate self-renewal mechanisms during stem cell development and malignant transformation. Furthermore, various tumors have been shown to include side populations (SP) of stem-like cancer cells expressing on their surface membrane transporters of the ATP-binding cassette family (ABC-family) responsible for genotoxic drug resistance, another well-described property of stem cells.

Aim: The aim of our study was to identify putative cancer stem cells in B-CLL that might drive tumorigenesis and be responsible for relapse of disease.

Methods: Expression levels of "stemness genes" following long-term in vitro culture of B-CLL patient derived peripheral blood mononuclear cells (PBMC) alone or in coculture with human stromal cells were determined by RTD-PCR. Overall changes in the gene expression profile of PBMCs and CD19+ MACS sorted B-CLL cells after long-term cultures were analyzed by Microarray-technology. For side population analysis of primary B-CLL samples, efflux of the fluorescent DNA dye Hoechst33342 was measured and the immunophenotype of SP cells was further characterized by flow cytometry.

Results: We detected a significant increase in expression levels of Gli1 and Notch1, key members of the SHH-and Notch signalling cascade during a culture period of 14 days. In contrast, expression levels of Notch1 mRNA of PBMCs remained unchanged during long term co-culture with human stromal cells. Microarray analysis of PBMCs and CD19+ MACS sorted B-CLL cells before and after long-term culture revealed 44 differentially regulated genes of which candidates with highest changes in expression could be classified to Bcell tumorigenesis and stem cell biology. By examining Hoechst 33342 efflux capacities, side population (SP) cells within PBMCs from B-CLL patients were identified in 9 of 20 samples and shown to accumulate over time in vitro. SP cells additionally showed coexpression of the B-CLL-specific surface markers CD5 and CD19.

Conclusions: Stemness genes are expressed in B-CLL, however, whether the observed changes in gene expression result from an alteration of expression patterns or a selection of cells over prolonged culture periods, remains uncertain. Background: The KIT mutation D816V is associated with autonomous proliferation of mast cells (MC) and is detectable in most patients with systemic mastocytosis (SM), including those who have an associated hematologic non-MClineage disease. Recently, KIT D816V was also reported to be expressed in patients with acute myeloid leukemia (AML). However, it was not clarified whether these patients have coexisting (occult) SM.

Methods and results: We investigated neoplastic cells in 113 patients with AML for expression of KIT D816V by RFLP analysis. In 7/113 patients (6.2%), KIT D816V was detectable. After a thorough histologic and biochemical analysis, all 7 cases were found to have associated SM. Microdissected tryp-tase+ MC in these patients displayed KIT D816V in all cases tested, whereas CD34+ blast cells exhibited KIT D816V in only 2/5 patients examined. In one patient with AML, SM without KIT D816V was detected. In all other patients, no associated SM was found, and leukemic blasts were negative for KIT D816V.

Conclusions: In summary, our data show that KIT D816V in AML is highly associated with co-existing SM (SM-AML). Moreover, our data show that AML blasts in these patients may lack this transforming mutation, which may be of importance when designing clinical AML-trials with specific targeted drugs directed against KIT D816V.

A multigenic approach to predict breast cancer risk

Background: In the biology of complex disorders, such as breast cancer, interactions among genetic factors may play an important role and theoretical considerations suggest that gene-gene interactions are quite common in such diseases. There have been many studies reporting association between genetic polymorphisms and susceptibility to breast cancer. Most of the studies have used a candidate-gene approach, investigating only one polymorphism at a time. Since carcinogenesis is usually a multistep and multigenic process, it is unlikely that one single genetic polymorphism would have a dramatic effect on cancer risk. Therefore, single-gene studies are likely to provide limited value in predicting risk. A multigenic approach, which assesses the combined effects of a panel of polymorphisms in the same and different pathways, may detect synergistic interactions between individual polymorphisms and enhance the predictive power.

Methods: In this case-control study with 500 breast cancer patients and 500 population-based healthy sex-and agematched control subjects, we applied a multigenic approach to examine the associations with breast cancer risk of a comprehensive panel of 16 selected polymorphisms in a variety of pathways using classification tree analysis (CART). All polymorphisms were determined by 5'-nuclease assays.

Results: Overall, 79.6% of all breast cancer patients and 80.6% of all control subjects were correctly classified within the set of 1000 cases on the basis of their individual genetic profile by the classification procedure. When the original data set was divided into a learning and independent test set, the classification tree correctly classified 85.3% of the breast cancer patients and control subjects in the learning set. Applying the constructed tree model to the independent test set, 73.2% of the breast cancer patients and 63.3% of the control subjects could correctly classified in the test set. CART analysis of the data identified the heterozygous vascular endothelial growth factor (VEGF) and matrix metalloproteinase 3 (MMP3) genotype and homozygous cyclooxygenase-2 (PTGS2) mutant as the initial splits, indicating that these genotypes exert the greatest impact on the classification process. Breast cancer patients were primarily indicated by 30 distinct genetic profiles. The odds ratio of these genetic risk profiles for breast cancer was 16.12 (95% confidence interval 11.09-23.49). 5 genetic profiles formed homogenous breast cancer subgroups and represented highest risk genetic profiles.

Conclusions: This is the first comprehensive study to use a multigenic analysis for breast cancer and the data suggest that individuals with distinct genetic profiles are at an increased risk for breast cancer, confirming the importance of taking a multigenic approach for risk assessment.

Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia -long term results of a randomized phase III study P. Grossschmidt 1 , E. Koller 2 , W. Linkesch 3 , D. Nachbaur 4 , P. Kier 5 , D. Geissler 6 , G. Fischer 7 , K. Geissler Background: Hematopoietic growth factors are used for more than 15 years for prophylaxis and therapy of chemotherapy-associated neutropenia. Although the benefit of G-CSF application for the amelioration of chemotherapy-associated neutropenia has been shown in numerous studies, the information on the influence of G-CSF on long term results of these studies is limited.

Methods: In 1997 we reported a study, in which G-CSF has been administered as an adjunct to induction chemotherapy for acute lymphoblastic leukaemia. Patients were randomized to receive no growth factor or G-CSF (5 mcg/kg/d sc) starting on day 2 of chemotherapy until granulopoietic reconstitution at the end of induction chemotherapy. 25 patients were randomized in the G-CSG group and 26 patients were included in the control arm. We here report a follow up of this study by collecting information from participating centers on the course of disease in study patients during the last 10 years.

Results: G-CSF markedly ameliorated neutropenia during induction chemotherapy because the median proportion of days with neutropenia less than 1000/mcl was 29% in the G-CSF group as compared with 84% in the control arm. More importantly, G-CSF significantly reduced the incidence of febrile neutropenia (12 v 42% in controls) and documented infections (40 v 77%). No significant differences were found with regard to requirements for red blood cell transfusions and platelet concentrates. After phase I of induction therapy the remission rate was 96% in the G-CSF group and 80% in control patients. There was no statistically significant difference (by the chi square test) in the 10 year survival, which was 40% in the G-CSF group and 36% in the control group. There were not reported any cases of secondary malignancy.

Results: Our results indicate that G-CSF administered as an adjunct to induction chemotherapy markedly reduces infect related morbidity during treatment but does not contribute to improve long term survival in these patients. Some examples based on a patient with 1.7 m² BSA and 70 kg body weight:

If there are six cycles of chemotherapy the drug loss e. g. of Pemetrexed adds up to 1020 mg, which amounts to 3251 €. Instead of the planned 5100 mg only 4080 mg are applied to the patient. Topotecan will be applied for five days. If there are six cycles of chemotherapy the drug loss adds up to 15 mg, which amounts to 1398 €. Instead of the planned 76.5 mg only 61.5 mg are applied to the patient. Results: A deficit from five to ten percent will be accepted. But in the individual case it is not shown which percentage of dosage loss could lead to an unacceptable loss of efficacy. Switching the infusion set because of final rinse of a chemotherapy or mid-cycle rinse between a poly-chemotherapy is not recommended. The one reason is the absence of aseptic procedure and the second reason is the staff safety. The principle of ALARA (As Low As Reasonable Achievable) has to be observed when handling with anticancer drugs.

Conclusions: The economical deficit of the anticancer drug loss due to the infusion set is notable. The introduction of a new device (e. g. "Spike with CLAVE ® and extension set", Biomedica) to administer infusion chemotherapy is for economical reasons immediately necessary. Background: Mastocytomas are among the most frequent neoplasms in canines. Aggressive mastocytomas usually are resistant against conventional therapy and the prognosis is grave. Therefore, current research focuses on new targets in neoplastic mast cells (MC) and the development of targeted drugs. Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a survival-enhancing molecule that is expressed in various neoplastic cells.

Methods: We examined the expression of Hsp32 (HO-1) in primary canine MC as well as in the canine mastocytoma cell line C2. Expression of the Hsp32 protein was examined by immunocytochemistry and Western blotting, and expression of Hsp32 mRNA by RT-PCR. To define the functional role of Hsp32, two novel Hsp32-targeting drugs, pegylated zinc-protoporphyrin (PEG-ZnPP) and styrene maleic acidmicelle-encapsulated ZnPP (SMA-ZnPP), were applied.

Results: As assessed by immunocytochemistry and Western blotting, primary neoplastic MC and C2 cells were found to express the Hsp32 protein in a constitutive manner. Moreover, we were able to show that C2 cells express Hsp32 mRNA. Exposure of C2 cells to hemin (10 µM) resulted in an upregulation of expression of Hsp32. Both Hsp32-targeting drugs, PEG-ZnPP and SMA-ZnPP, were found to inhibit the proliferation of C2 cells and of neoplastic MC. The growthinhibitory effects of PEG-ZnPP and SMA-ZnPP were timeand dose-dependent (IC 50 : 1-20 µM), and associated with apoptosis.

Conclusions: Hsp32/HO-1 is an important survival factor and interesting new target in neoplastic canine MC. Clinical trials with Hsp32-targeted drugs are now warranted to define the in vivo antineoplastic efficacy of these new drugs. Background: Haematological autoimmune complications are relatively common in CLL but are much less common in NHL. In large studies the prevalence of autoimmune hemolytic anemia (AIHA) is 1.57%, of autoimmune thrombocytopenia (AITP) is 0.76% and of Evans-syndrome 0.18%.

Methods: We have analysed 136 individual cases of NHL (excluding CLL) associated AIHA, AITP and Evans-syndrome reported in the literature (88 cases of AIHA, 34 cases with AITP and 14 with Evans-syndrome) with regard to demographic factors, prevalence in subtypes and treatment response.

Results: The median age of all patients was higher than in idiopathic cases. In contrast to idiopathic AIHA and AITP there was no female sex prevalence. In AIHA the sex prevalence was different in subtypes. AIHA and AITP occurred in all subtypes in NHL with the exception of AIHA in mantle cell-lymphoma (no case). There was of high prevalence of localized of extranodal early stage lymphomas (in particular in DLCL). In both AIHA and AITP sustained responses to steroids and HD-IgG were uncommon. Splenectomy had high efficacy only in SLVL. Surgical removal of extranodal lymphomas and/or chemotherapy was effective in about half of the cases. The mortality was higher in AIHA than in AITP. Rituximab was effective in some highly refractory cases of AITP and AIHA.

Conclusions: This compilation of data indicates a complex relation of lymphoma and AIHA/AITP and warrants more attention and specific studies. Background: In patients with systemic mastocytosis (SM), several activation-linked cell surface antigens such as CD2 or CD25, are "overexpressed" on neoplastic mast cells (MC) compared to normal MC, and thus can be employed as diagnostic parameters. The ectoenzyme E-NPP3 (CD203c) is a novel activation-linked basophil antigen that is expressed at low levels on normal MC.

Methods: Using multicolor flow cytometry, we examined the expression of CD203c on bone marrow MC in 85 patients with SM, in normal bone marrow (n = 38), and in primary lung MC (n = 3). Lung MC or neoplastic MC were incubated with an anti-IgE antibody or stem cell factor before being examined for CD203c expression. In patients with ASM or MCL, we examined expression of CD203c-mRNA in highly purified FACS sorted MC by RT-PCR.

Results: In patients with SM, MC expressed significantly higher levels of CD203c compared to normal bone marrow. There were no significant differences in expression of CD203c among the SM variants analyzed, although slightly lower amounts of CD203c were detected in those with SM-AHNMD. As assessed by RT-PCR, purified neoplastic MC as well as HMC-1 cells were found to express CD203c mRNA. Incubation of lung MC or neoplastic MC with anti-IgE resulted in upregulation of expression of CD203c. However, in patients with SM with anaphylaxis, MC did not exhibit higher baseline levels of CD203c compared to SM patients without anaphylaxis.

Conclusions: CD203c is a novel activation-linked MC antigen, that is upregulated in response to IgE receptor crosslinking and is overexpressed on neoplastic MC in SM. Background: Tumor growth requires the formation of new blood vessels, a phenomenon known as angiogenesis. The most important regulator of angiogenesis is vascular endothelial growth factor (VEGF). A common 936 C/T polymorphism in the VEGF-gene has been associated with different VEGF plasma levels according to allele status and influences the risk of developing primary lung cancer and breast cancer. Therefore, this variant might be a risk factor for colorectal cancer (CRC).

Methods: In the present case-control study, VEGF genotype was determined in 427 patients with histologically verified CRC and 427 age and sex-matched healthy control subjects. Genotypes were analyzed by a fluorogenic exonculease assay (TaqMan ™ ). P-value for age at diagnosis was analyzed by student's t-test, p-values for tumor characteristics were determined by Pearson's Chi-square-test. Threshold for significance was p < 0.05.

Results: At the time of diagnoses, patients were between 29 and 83 years of age, with a mean age of 61 ± 10.9 years. Carriers of the 936T-allele were found slightly more frequent among controls (27.2%) than among patients (22.5%), but this difference did not reach statistical significance (p = 0.07). Furthermore, no correlation was found between this 936 C/T variant and tumor characteristics like size, histological grading, positive regional lymph node metastases or tumor stage.

Conclusions: Therefore, we conclude that the 936 C/T polymorphism is not associated with individual susceptibility to colorectal cancer.

Association of common Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk Background: Integrins, such as α2β1, αIIbbβ3 and αvβ3 have been suggested as key players for cancer development and progression. Several polymorphisms affecting these molecules, two in integrin α2 (ITGA2 807C>T and 1648G>A) and one in β3 (ITGB3 176T>C), influence their levels, structure and possibly their function. To analyze the role of ITGA2 and ITGB3 polymorphisms for colorectal cancer risk and clinical presentation we performed the following case-control study.

Methods: 433 consecutive colorectal cancer patients and 433 healthy sex-and age-matched control subjects were investigated. ITGA2 and ITGB3 polymorphisms were determined by 5′-nuclease assays.

Results: The ITGA2 807C>T polymorphism was associated with reduced colorectal cancer risk. In a codominant model, the odds ratio for each additional 807-T allele for colorectal cancer was 0.77 (95% confidence interval 0.64-0.94; p = 0.011). The ITGA2 1648G>A and the ITGB3 176T>C polymorphism were not associated with colorectal cancer. None of the three polymorphisms investigated was linked to tumor size, histological grade, presence of primary lymph node metastases, tumor stage or age at diagnosis.

Conclusions: Polymorphic genetic variations of integrins could modify the risk of colorectal cancer. The precise mechanism remains to be determined, but likely involves dysregulated signalling pathways. Background: Current evidence suggests an important role for antigenic selection in the establishment and evolution of B-CLL and a function for T cell initiated signalling in the maintenance or control of the disease is very likely. This argument is supported by the finding that CLL samples contain a number of clonal T cell populations with skewed T cell receptor (TCR) V gene usage. The aim of our study is to gain a better perspective on the complex interactions between T and B-CLL cells.

Methods: Circulating T cell populations from 90 B-CLL patient samples were characterised by CDR3 spectratyping using TCR beta family-specific primer sets to determine the TCR usage and clonality of the CD4+ and CD8+ populations. CLL samples were further characterised regarding their B cell receptor (BCR) V gene usage, mutation status, and other clinical and prognostic parameters. Additionally, we analysed the HLA status of patients with V genes 3-21 and 3-7 in order to further evaluate the antigenic input.

Results: BCR VH genes were sequenced and mutated VH genes were found in 67% of patients while 33% of cases were unmutated. Interestingly, the incidence of the VH 1-69 gene that is commonly reported in the literature was lower than expected, while the V genes 4-34, 3-21, 3-7 and 3-23 together made up 36% of cases. The CDR3 regions of BCRs using VH 3-21 and 3-7 were highly conserved between B-CLL clones from different patients, suggesting a strong antigenic selection. Analyses of the HLA status of patients with V gene 3-21 and V gene 3-7 revealed distinct DRB1 alleles overrepresented in these groups compared to the allele frequency of the European population. Analyses of the TCR genes demonstrated expression of all 20 TCR beta family V genes in our patients. However, the TCR CDR3 size distribution pattern revealed a high frequency of oligoclonal/monoclonal T cells in the CD8+ T cell subset (over 50% of all TCR V genes analysed), while in the CD4+ population only around 10% clonality was observed. Additionally, clonality within the CD4+ T cell populations was more common in cases from unmutated CLL. In four patients with a rearranged BCR VH 3-21 gene we found T cell clones using the TCR BV 3 gene on both CD4+ and CD8+ subsets. TCR sequence analysis demonstrated a conservation of the CDR3 regions between these T cell clones, suggesting a common antigenic trigger. VH 3-21 has been shown to be an independent prognostic marker in CLL irrespective of mutational status.

We present a first analysis of the clonal T cell repertoire in CLL patients in conjunction with BCR V gene usage. We observed an association between identical monoclonal TCRs and the usage of certain CLL BCR V genes. Analyses of the HLA status of patients with VH genes 3-21 and 3-7 demonstrated a distinct skewing in the MHCII locus in each group. The role that such clonal T cells may play in the propagation or control of the malignant B-CLL clone is currently being investigated in various functional assays. Background: Sweet's syndrome or "acute febrile neutrophilic dermatosis" is an uncommon skin disease occurring mainly in women at mid-life characterised by acute onset of tender erythematous nodules located on head, neck, upper extremities and trunk, usually accompanied by fever and malaise. Up to 20% are accompanied by malignancies (paraneoplastic), mainly hemopathies. Drug induced Sweet's syndromes have repeatedly been descibed.

Case report: We report on a 64-year-old woman suffering from nephrotic syndrome due to membranoproliferative glomerulonephritis since August 2005. Twelf months later a light chain myeloma lambda, stage II was diagnosed. She was treated with bortezomib and dexamethasone as first line therapy for five cycles when she presented with fatigue and onset of multiple round solid pruritic but indolent erythematous plaques on her trunk and shoulders. Following further treatment, a deterioration and dissemination of those skin lesions, which coalesced to itching plaques, and progressive asthenia but no fever were observed. Skin biopsies confirmed the diagnosis of Sweet's syndrome. Within 6 days after the discontinuation of treatment and initiation of continuous corticoid treatment the cutaneous lesions as well as the constitutional symptoms resolved and did not reappear during the next four months.

Despite this atypical occurrence of Sweet's syndrome, its association with bortezomib may be considered. Background: Due to the increasing life expectancy in our society the management of geriatric patients suffering from hemato-oncological disease has become a central issue. Although many treatment studies for acute myeloid leukaemia (AML) patients have been reported, the percentage of geriatric patients in theses studies is usually low. Reports on the experience regarding management of these patients are required.

Methods: We report on our experience in the management of patients with AML older than 70 years, who were treated at our department between 11/03 and 12/06. 17 patients older than 70 years (median age 76 years, ranges 70-94) were diagnosed as AML by bone marrow puncture.

Results: Because of comorbidity and poor performance status 7 patients were treated by supportive care only. In 10 patients AML-chemotherapy was administered. Induction chemotherapy consisted of daunorubicin 45 mg/m 2 /d d1-3, etoposide 100 mg/m 2 /d d1-5, and ARA-C 2 × 100 mg/m 2 /d d1-7. In 1 patient with secondary AML idarubicin 10 mg/m 2 /d d1-3 was administered instead of daunorubicin. In case of non achievement of CR after the first chemotherapy cycle a second induction therapy was given (2+5+5, MIDAC). For patients achieving remission intermediate dose ARA-C 2 × 1 g/m 2 /d d1,3,5 was given as consolidation treatment. 6 of 10 patients (60%) who were treated with intensive chemotherapy achieved CR. 2 patient died during the first 6 weeks following initiation of chemotherapy. The median duration of remission was 11 months. The 2 year survival of these patients is 44%. Patients treated with supportive care alone had a median survival of 1 month.

Conclusions: Our results indicate that intensive chemotherapy is feasible in patients older than 70 years. The toxicity profile is acceptable in these patients and the remission rate is in the range reported in studies which included adult patients with lower age. For some patients older than 70 years chemotherapy offers the chance to achieve complete remission and to regain their living conditions they had before development of AML. Background: The intrinsic antiangiogenic protein vasohibin has been shown to be a negativ feedback-regulator of VEGF and bFGF signalling in human endothelial cells. It has been reported recently, that VASH1 acts specifically on endo-thelial cells. Therefore, VASH1 has been considered as a canditate for antiangiogenic therapies, but intracellular processing and secretion of VASH1 are still unknown, due to the lack of a classical signal peptide sequence in the protein. Moreover, a novel alternative splicing isoform (VASH1B) was studied for its antiangiogenic effects in comparison to the main VASH1 product (VASH1A).

Methods: The regulation of VASH1 gene expression by angiogenic cytokines (TGF-β1, bFGF and VEGF) was analyzed by RT-qPCR and Western blots. Subcellular localization studies were performed by transfection of FLAG-tagged proteins in primary endothelial cells and immunofluorecence analysis with wheat germ agglutinin (WGA) for glycoproteins of the Golgi apparatus, von Willebrand Factor (vWF) for secretory organelles and with DAPI for cell nuclei. Moreover, cell proliferation, migration and capillary formation was studied 5 days after adenoviral transfection of GFP, VASH1A and VASH1B. Cell numbers were determined by a Bürker-Chamber, cell migration in scratch assays and capillariy formation in Matrigel ® -assays.

Results: VASH1A and 1B were upregulated only by VEGF stimulation. Both isoforms localized to cytoplasm and nucleus, due to a N-terminal nuclear localization sequence. In contrast mVASH, lacking the NLS domain, was localized in vesicles in the cytoplasm and did not show any colocalization with Golgi Apparatus and endoplasmatic reticulum. No VASH1 protein or proteolytical fragments were detected in the respective culture supernatants. Adenoviral overexpression of the alternative splicing isoform VASH1B in endothelial cells resulted in a significant inhibition of cell growth, migration and capillary formation. This was not observed with the major isoform VASH1A.

Conclusions: In contrast to previous reports we were not able to demonstrate efficient secretion of the VEGF target protein VASH1 by primary endothelial cells. Both isoforms of human VASH1 localized to the cytoplasm and nucleus, whereas murine VASH1, lacking the NLS domain, localized only to cytoplasmatic vesicles. Moreover, antiangiogenic effects were only observed with the alternative splicing variant VASH 1B and not with the major form VASH1A. Based on these observations endothelial cell specificity and intracellular interaction partners mediating the antiangiogenic effects of VASH1B still remain to be investigated.

M. Kneidinger 1 , K. Gleixner 1 , A. Böhm 1 , M. Weghofer 2 , C. Lupinek 2 , S. Vrtala 2 , R. Valenta 2 , G. Superti-Furga 3 , F. Y. Lee 4 , P. Valent 1 Background: Dasatinib (BMS354825) is a small molecule-type inhibitory drug that blocks several tyrosine kinases including PDGFR, KIT, BCR/ABL, and several src kinases. Dasatinib has recently been introduced as a new effective antileukemic drug in patients with imatinib-resistant chronic myeloid leukemia. However, because of the many targets of dasatinib and the broad range of potential target-cells in physiologic and pathologic tissues, dasatinib has recently been examined for its immunosuppressive and anti-inflammatory effects.

Methods and results: We here report that dasatinib at 1 µM completely blocks the anti-IgE-induced release of histamine in human blood basophils in healthy subjects. The effects of dasatinib on histamine secretion in basophils were dosedependent (IC 50 : 50-100 nM). Dasatinib was also found to block recombinant allergen-induced release of histamine from human basophils in sensitized individuals. In addition, as assessed by flow cytometry, dasatinib (1 µM) was found to inhibit the IgE-dependent upregulation of several activationlinked antigens, including aminopeptidase N (CD13), LAMP-3 (CD63), endolyn (CD164), and the basophil-specific ectoenzyme E-NPP3 (CD203c) on the cell surface of human basophils. The effects of dasatinib on upregulation of basophil differentiation antigens were found to be dose-dependent and were seen in normal subjects as well as in allergic individuals.

Conclusions: Dasatinib blocks IgE-mediated activation and histamine release in human blood basophils. These antiallergic effects of dasatinib may have clinical implications and may point to additional indications for this multifunctional drug. Methods and results: We describe a patient suffering from ASM in whom MC were particularly immature and showed a destructive sarcoma-like growth with infiltration and tumor-formation in the skeleton. Unexpectedly, these immature MC were found to be tryptase-negative cells by routineimmunohistochemistry. In addition, MC did not stain positive for chymase. To establish the correct diagnosis, additional immunohistochemical markers and a highly sensitive staining protocol were applied. In these stains, neoplastic MC were demonstrated to co-express KIT, histidine decarboxylase (HDC), and low amounts of tryptase together with CD25, CD44, and CD63. In addition, the anti-apoptotic molecules Mcl-1 and Bcl-2 were detectable in neoplastic MC. Despite therapy with interferon-alpha and cladribine (2CdA), further progression of the disease into mast cell leukemia developed.

Conclusions: Progression and de-differentiation of MC in SM may be associated with partial loss of MC differentiation antigens including the key marker enzyme tryptase. In such cases, it is of importance to apply additional diagnostic markers and a highly sensitive staining protocol. Aim of this study was to assess "real life data" concerning the clinical outcome of myeloma treatment with B. and comparing them with published data.

Methods: Pts. were identified using a data base search of the hospital pharmacies records. All pts. treated with at least one cycle of B. were included in this retrospective analysis. Established risk factors for myeloma (ISS, cytogenetics) were recorded. Besides remission status and overall survival clinical surrogate parameters such as paraprotein, beta-microglobulin, serum creatinin and serum albumin were evaluated. In addition, adverse effects of treatment with B were documented.

Results: A total of 34 pts. were identified (19f / 15m) within the selected time period. 3 patients had a diagnosis different from MM (1 tubulopapillary pleural mesothelioma, 1 DLBCL, 1 LPICC). The subtypes of MMs included IgGkappa (n = 18), IgG-lambda (n = 5), IgA-lambda (n = 3), IgAkappa (n = 2), Bence-Jones-kappa myeloma (n = 3), and Bence-Jones-lambda myeloma (n = 1). The mean pts. age was 63 (range 46-80) years at the time of diagnosis. Two patients received B. within clinical studies, one as 1st line treatment in the VISTA study and one as 2nd line treatment in the Doxil-MMY-3001 study. B. was fairly well tolerated and dose reductions were rarely necessary. Clinical responses were seen in 38.2% (13/34) of the pts. (including CR, VGPR, GPR, and PR). Due to the early treatment phase or ongoing follow-up evaluation of the remission status is still pending in 8 pts. The remaining pts experienced either stable (8/35) or progressive disease (5/35). Updated results on response and survival as well as adverse events of the patients cohort will be presented.

Conclusions: Treatment with B. proved to be effective and safe in every day clinical practice leading to results comparable to published data on multiple myeloma.

A common polymorphism in the gene for cyclooxygenase-2 (PTGS2 8473T>C) and its association with prostate cancer risk: A population-based study Background: Cyclooxygenase-2 (COX-2) is involved in carcinogenesis, immune response suppression, apoptosis inhibition, angiogenesis, tumor cell invasion, and metastasis. The gene for COX-2, designated as PTGS2, carries a common polymorphism at position 8473 in the 3'-untranslated region (PTGS2 8473T>C), which has been associated with susceptibility to malignant disease.

Methods: To investigate the role of the PTGS2 8473T>C polymorphism for prostate cancer, we determined the prevalence of PTGS2 genotypes in 500 men with histologically confirmed prostate cancer and 500 male and age-matched control subjects. Genotypes were determined by a 5'-nuclease assay (TaqMan™). Finally, 95 samples were re-analyzed and results were identical for all samples. Statistical analysis was done using SPSS 11.0 for Windows. Numeric values were analyzed by Student's t-test, proportions of groups were compared by chi2 test. Odds ratios and 95% confidence intervals were calculated by logistic regression to estimate the risk for prostate cancer. Threshold for significance was p < 0.05.

Results: Genotype and allele frequencies were not significantly different between prostate cancer patients (TT: 42%, TC: 47%, CC: 11%) and control subjects (TT: 40%, TC: 49%, CC: 11%; p = 0.82). PTGS2 genotypes were furthermore not associated with age at diagnosis of prostate cancer (TT: 68 ± 7 years, TC: 69 ± 7; CC: 69 ± 7; p = 0.13). The study had a statistical power of 0.83 to detect or exclude an odds ratio of 1.7 for the homozygous PTGS2 8473-TT genotype.

Conclusions: We conclude that the PTGS2 8473T>C polymorphism in the gene encoding COX-2 does not contribute to prostate cancer risk.

Are patients with hemochromatosis potential blood donors? G. Leitner 1 , C. Kohl 1 , I. Rach 1 , J. List 1 , M. Horvath 1 , G. Weigel 2 , P. Höcker 1 Background: Hereditary hemochromatosis is one of the most common inherited disorders in Caucasians. A point mutation in the HFE gene is found in 85 to 100 percent of subjects leading to pathological iron metabolism and iron overload. Phlebotomy therapy has been the mainstay of treatment for hemochromatosis for 50 years. According to national and European guidelines the allogeneic use of packed red blood cells (PRBC) collected from hemochromatosis subjects is forbidden. In USA the FDA is less restrictive provided that these PRBCs fulfill the required quality criteria. The aim of this study was to investigate the quality of PRBCs collected from hemochromatosis subjects over a storage period of 42 days.

Methods: We collected 48 PRBCs using apheresis technology from patients who were diagnosed with hemochromatosis but still asymptomatic and therefor fulfilled eligibility criteria for blood donation (n = 8, median age 36 years, range 20 to 53). PRBCs were stored at 4°C (± 2°C) for 42 days To assess the extent of storage lesion we measured metabolic parameters (LDH, free hemoglobin K+, lactate), consumption of glucose, hemolysis and degradation of intracellular purines (ATP, ADP, AMP). Samples were drawn in weekly intervals till the end of shelf life.

Results: The mean haemoglobin (hb) content was 59.2 (± 3.7) g/unit and hemolysis was 0.17% (± 0.1%) at the end of storage. Leukocyte contamination was <1 × 10 6 in all units. The increase of metabolic parameters, as well as the consumption of glucose and the loss of intracellular purines was comparable with PRBCs collected from "normal" subjects.

Conclusions: Freshly collected as well as stored PRBCs from individuals with point mutation in the HFE gene fulfilled national and international required quality criteria for allogeneic blood transfusion. (Hemolysis <0.8% at the end of shelf life, hb content ≥ 40 g/unit, leukocyte contamination <1 × 10 6 / unit). Moreover implementation of hemochromatosis subjects as blood donors would probably counteract seasonal shortages in blood supply. Background: Androgen receptors (AR) are commonly expressed in invasive breast carcinoma. The prognostic significance of AR in survival has been shown in several studies. The influence of antiandrogens already was investigated in a small number of preclinical and clinical studies. Bicalutamide (Casodex ® ) is an oral nonsteroidal antiandrogen which is commonly used in prostate cancer.

Objectivs: The purpose of this study was to investigate the efficacy and tolerability of the antiandrogen Bicalutamide in male and female patients with AR positive metastatic breast cancer (MBC).

Methods: Between June 2004 and June 2005 one male and six female patients with histologically confirmed metastatic breast cancer were enrolled onto this clinical trial. All patients had received prior chemotherapy and all except one received prior hormonal therapy. Bicalutamide was administered orally at a dose of 50 mg one time daily. Patients were followed every 4 weeks by history, physical examination, haematology and biochemistry. Response evaluation by radiographic measurement was done after eight weeks.

Results: The median age was 62 (range 48-77), median ECOG performance status was 2 (range 1-3). Median number of prior chemotherapy was 3.8 (range 1-6) and median number of prior hormonal therapy was 2.6 (range 0-4). Bicalutamide was well tolerated. There were no adverse events due to study drug. Median duration of Bicalutamide therapy was 8.2 weeks (range 6-12). One response, of 12 weeks duration, was noted. Six patients had progressive disease.

Conclusions: We could not show any positive effect of Bicalutamide on disease control, but we could show the safe administration of antiandrogens in our female patients. Lack of our trial was the advanced disease and poor performance status of study participants. Further studies should investigate antiandrogens in AR positive earlier MBC. Background: Up to now, few data have been collected on the quality of life (QOL) of myeloma patients. Results of a recent study suggest that response to treatment is an important factor in this regard. Our aim was to further investigate the impact of response to treatment on the QOL of myeloma patients undergoing conventional chemotherapy.

Methods: We prospectively collected QOL data using the EORTC QLQ-C30 in a study comparing continuous versus intermittent prednisone plus VMCP in 292 newly diagnosed myeloma patients. A QOL-questionnaire was distributed to each patient at each visit. Using the official EORTC scoring manual, we analyzed the relationship of response to global QOL, all functional scales and the symptom scale fatigue.

Results: QOL data are available in 186 of 260 evaluable patients. Mean QOL scores during induction therapy were significantly associated with the quality of response achieved. This was still true for the following scales, if patients with progressive disease were excluded from the analysis: global QOL (P 0.02747), fatigue (P 0.00017), role functioning (P 0.04032, Figure) , cognitive functioning (P 0.0224), and emotional functioning (P 0.01274). When QOL at the last visit of induction treatment was analyzed, global QOL (P 0.02273), physical functioning (P 0.01541) and fatigue (P 0.004616) were significantly associated with quality of response. In the case of global QOL and fatigue this was still true when patients with PD were excluded (P 0.04991 and P 0.009635, respectively). Mean physical functioning and cognitive functioning during induction were also inversely correlated with time to first response (P 0.04025 and P 0.04674, respectively).

Conclusions: Quality of response during induction treatment significantly influences central parameters of QOL including cognitive function in myeloma patients undergoing conventional therapy. If patients with progressive disease are excluded, the magnitude of response is still associated with QOL. Even if survival cannot be prolonged by achieving a better response, myeloma patients might benefit from a better response by having a better quality of life. Results: After consideration of sub-and supermodels, the final model contains main effects of c-IPSS, age, gender and FAB and significant gender*age and age*FAB interactions, expressed by the following formula for the risk ratio: RR = c-ipss*.60 + gender*.24 + age66*.49 + fab_gr*.94 + gender_by_age*-.81 + age_by_fab*-.99

Conclusions: The simultaneous consideration of c-IPSS, age, gender and FAB confirms the prognostic impact of these characteristics on survival, showing the strongest main effects for c-IPSS and FAB. c-IPSS differentiates well in all gender*age*FAB-subgroups without indications of markedly different importance in specific subgroups ( no significant interactions between c-IPSS and other characteristics). Age and FAB do have strong additional prognostic impact, while gender shows a differential influence, favouring in younger patients males and in older patients females. The age*FAB interaction represents much more pronounced risk differences between RA/RARS vs. RAEB/RAEBt/CMML in younger than in older patients. Cytogenetics as expressed by c-IPSS has strong prognostic impact, comparable in magnitude to that of FAB. Age and gender show weaker main effects, but marked interactions. The fact that prognosis based either only on the c-IPSS or only on age, gender and FAB is clearly less powerful, underlines that c-IPSS and the other considered characteristics add independent explanatory power to a prognostic model and therefore have to be considered jointly. Ergebnisse: Spätestens 2 Stunden nach Beginn der Atemtherapie besserte sich der PaO 2 /FiO 2 Quotient auf Median 305 (229-480), die AF senkte sich auf 15/min (12-16) und spezifische Chemotherapie (Induktiontherapie/Reinduktion bei AML, VAIA bei Sarkom, Carboplatin/Docetaxel bei Adenocarcinom) bzw. antibiotische Therapie konnte fortgeführt bzw. gleichzeitig zur Beatmung eingeleitet werden. Der Patient mit Agranulozytose erhielt Granulozytenkonzentrate, G-CSF und Breitspektrum AB-Therapie bei SIRS und transfusionsassoziertem Lungenversagen. Alle Patienten sprachen auf die krankheitsspezifische Therapie an und konnten nach 3 Tagen Median (1-6) von der nicht invasiven Atemtherapie entwöhnt werden. Durch rechtzeitigen Beginn der nicht invasiven Therapie wurde diese von den Patienten gut toleriert, und es musste kein einziger Patient intubiert werden. Von den Patienten mit akuter myeloischer Leukämie erzielten 2 Patienten eine komplette hämatologische Remission und sind zurzeit noch in Remission. Bei diesen Patienten wäre unter konventioneller Therapie eine Intubation nötig gewesen und in der Regel keine Induktionschemotherapie erfolgt. Der Patient mit Frührezidiv wies einen chemotherapierefraktären Krankheitsverlauf auf, blieb aber in weiterer Folge ohne respiratorische Komplikationen. Auch die Patienten mit Synovialsarkom und Adenokarzinom erzielten eine partielle Remission und konnten ohne respiratorische Probleme entlassen werden. Der Patient mit Agranulozytose und Pneumonie erreichte vollständige Knochenmarksregeneration ohne eine zusätzliche beatmungsasso-ziierte Pneumonie zu erleiden und ist seit 2 Jahren krankheitsfrei.

Schlussfolgerungen: Eine rechtzeitig durchgeführte nicht invasive Atemtherapie ermöglicht bei hämato-onkologischen immunsuprimierten Patienten in der Regel eine ausreichende Oxygenierung und erlaubt damit weiterführende spezifische Therapien ohne das für dieses Patientengut verheerende Risiko einer endotrachealen Intubation. Sie kann in selektiven Fällen lebensrettend sein. Background: VTD was reported to be an active salvage regimen in patients with relapsed/refractory multiple myeloma (MM). Since initial results with VTD as frontline therapy were also promising, we used VTD as induction treatment prior to autologous transplantation in MM patients with particularly high tumor burden.

Methods: Velcade was administered at 1.3 mg/m 2 on days 1, 4, 8, and 11; thalidomide was given as a daily dose of 100 mg; dexamethasone (20 mg per os) was given on days 1, 2, 4, 5, 8, 9, 11, and 12 . Four cycles were scheduled every 3 weeks.

Results: We here report on three patients (age 36, 38, and 50 years) with newly diagnosed MM and high tumor mass at presentation (patient 1: Bence-Jones kappa MM with 95% plasma cell infiltration, serum free-kappa light-chains 4000 mg/l; patient 2: IgG-kappa MM with serum IgG >9000 mg/dl, bulky plasmacytomas in the iliac bones; patient 3: IgA-lambda MM with 70% plasma cells in the bone marrow, IgA 4500 mg/dl, plasmacytoma in the os sacrum >10 cm in diameter). Genetically, all 3 patients corresponded to the hyperdiploid variant (multiple trisomies, absence of del(13q14) and del(17p13)); patient 1 also had a t(11;14) and gain of chromosome 1q21. VTD resulted in a paraprotein reduction of at least 75% already after cycle 1. Rapid tumor mass reduction was not associated with signs of tumor lysis, and patient 1 had a significant improvement in renal function (serum creatinine from 2.4 to 1.3 mg/dl). After 4 cycles of VTD, patients 1 and 2 achieved a CR including a normal kappa/lambda ratio in the free-light-chain assay (patient 3 still ongoing). Patient 1 has already completed G-CSF primed peripheral stem cell collection and autologous transplantation. Toxicity of VTD was mild (transient nausea and diarrhea in patient 2), in particular no peripheral neuropathy (grade 2 or higher).

Conclusions: Induction treatment with VTD results in an effective tumor mass reduction already within one cycle and should be further evaluated in MM patients in need of rapid disease control. Background: Cell cycle arrest and apoptosis induction are generally regarded as the most important mechanisms by which p53 exerts its tumor suppressive effect. Two main targets have been identified in this respect: (1) p21 Waf1 , as an essential regulator of cell cycle arrest downstream of p53, and (2) PUMA, as the largest single contributor towards p53induced cell death. While deactivation of p53 in mice leads to a 95% incidence of tumors (71% thymic lymphomas) and death within 7 months, the loss p21 Waf1 or PUMA by themselves does not result in a tumorigenic phenotype. Thus, simultaneously disabling these targets may be required to recapitulate the p53-null phenotype in mice.

Methods: We generated mice that were doubly-deficient for Puma and p21 Waf1 . Ex-vivo thymocytes were analysed for resistance to γ-irradiation. Induction of apoptosis was meas-ured by FACS following Annexin V staining and 7aad incorporation. For cell cycle analysis, the absolute number of cells in S-phase was determined by staining for incorporated BrdU, and DNA content was measured using propidium iodide. Mice were followed for the development of spontaneous and radiation-induced tumors and sacrificed when moribund.

Results: Thymocytes isolated from PUMA/ p21 Waf1 double knockout mice (DKO) are resistant to apoptosis and continue to actively cycle and synthesize DNA following γ-irradiation. Thus, DKO ex-vivo thymocytes behave as would be expected from the loss of PUMA and p21 Waf1 . Surprisingly, DKO mice are resistant to the development of spontaneous tumors, with only an 11% tumor incidence after 18 months of age, and none within the lymphoid system. Furthermore, the loss of both PUMA and p21 Waf1 protects mice from the development of thymic lymphomas following whole-body irradiation. Isolation of the lymphoid organs following whole-body irradiation demonstrated little loss of total cellularity within the thymus of DKO mice, again demonstrating, as with the exvivo thymocytes, their resistance to radiation-induced apoptosis. However, despite the lack of this p53-mediated tumor suppressor function, DKO mice remain tumor-free 250 days postirradiation.

Conclusions: Loss of both PUMA and p21 Waf1 protects from cancer development. Additionally, the p53-mediated induction of cell cycle arrest and apoptosis in response to irradiation and DNA damage do not appear to be essential for tumor suppression. In DKO mice, thymocytes harboring DNA damage induced by radiation treatment are not cleared by apoptosis. Yet this pool of 'mutated' cells are unable to give rise to a tumor clone. Thus, significant and perhaps more important tumor suppression mechanisms still exist despite the loss of both PUMA and p21 Waf1 , or are activated because of it. The urokinase system has originally been implicated to assist the angiogenic process by it's proteolytic properties, thereby supporting new blood vessel formation in malignant diseases. It is now becoming increasingly evident that uPA additionally elicits many pro-angiogenic responses like differentiation, proliferation and cell migration in a non-proteolytic fashion via induction of intracellular signal transduction. Thereby, high malignancy in certain tumors has been shown to be accompanied by high levels of urokinase secretion.

In this study we demonstrate that in endothelial cells uPA protects against apoptosis by transcriptional upregulation of inhibitor of apoptosis proteins (IAPs), among them most prominently the X-linked inhibitor of apoptosis protein (XIAP). In contrast to canonical growth factors, like vascular endothelial growth factor (VEGF), uPA elicits anti-apoptosis independently of the PI3-kinase pathway. uPA-induced cell survival is dependent on the type of extracellular matrix used indicating the involvement of integrin adhesion receptors. Thereby, uPA induces phosphorylation of the CDC42 downstream effector p21-activated kinase 1 (PAK1), which leads to IkappaB kinase alpha (IKKa) phosphorylation, a prerequisite for NFkappaB activation. Blocking NFkappaB by using the specific NFkappaB inhibitor BAY 11-7082 or by adenoviralmediated overexpression of its inhibitor, IkB, inhibits uPAinduced XIAP expression as well as uPA-induced cell survival. Downregulating XIAP expression by small interfering RNA techniques significantly reduces cell survival efficiencies of uPA in endothelial cells.

From these data we conclude that uPA activation, which is a main player in endothelial cell migration and invasion, provides an additional, PI3-kinase independent cell survival mechanism.

Clinical scale propagation of functional cord blood MSC in a humanized system A. Reinisch 1,4 , C. Bartmann 1, 2, 4 Methods: We analyzed isolation and proliferative potential of human UCB-MSC as compared to BM-MSC under optimized ex vivo culture conditions. We further investigated the impact of human platelet lysate (HPL) as an alternative to replace FBS for clinical scale expansion of MSC. Progenitor cell function was determined by CFU-F assays and correlated to proliferative senescence. MSC functions were tested in hematopoiesis support, vascular regenerative and immune modulation potency assay.

Results: MSC could be reproducibly propagated from UCB with and without FBS. MSC propagation was effective in 46% of UCB samples compared to 100% of BM samples. Once established, the proliferation kinetics of UCB-MSC did not differ significantly from that of BM-MSC under optimized culture conditions resulting in >50 population doublings after only 10 weeks. A clinical quantity of 100 million MSC could be obtained from UCB-MSC despite minute primary cell amounts. Immune suppression and vascular regenerative function in vitro could be shown for UCB-MSC propagated under both culture conditions. Ex vivo expansion of UCB-derived CD34 + /CD38 + hematopoietic progenitors and was more efficient with HPL compared to FBS cultured UCB-MSC.

Conclusions: We demonstrate for the first time that human MSC can be obtained and propagated to a clinical quantity from UCB in a completely FBS-free system although.

Surprisingly, our data argue against a generally superior proliferative potential of UCB-MSC compared to adult BM-MSC. The efficient propagation of UCB-derived CD34 + /CD38 -HSC encourages further studies to develop effective strategies for UCB-SC expansion for adult patients.

Einstellung zur Reanimation von Patienten mit fortgeschrittener, unheilbarer Erkrankung bei Aufnahme auf einer Palliativstation -eine retrospektive Studie V. Requat 1 , B. Hammerl 1 , C. Geissler 1 , G. Fischer 2 , K. Geissler 1,2 1 5. Medizinische Abteilung mit Onkologie und Palliativstation, Krankenhaus Hietzing, Wien, Österreich; 2 Ludwig Boltzmann Institut für klinische Onkologie, Wien, Österreich Grundlagen: Die weitestgehende Berücksichtigung der Patientenautonomie (mutmaßlicher Patientenwille) ist einer der zentralen Grundsätze in der Palliativmedizin. Aus diesem Grund ist es von besonderem Interesse, die Einstellung der Patienten auf einer Palliativstation zur Reanimation zu untersuchen.

Methodik: Von insgesamt 365 Fragebögen, die bei Aufnahme auf der Palliativstation einer onkologischen Abteilung im Zuge eines Assessments durch den jeweils zuständigen Stationsarzt ausgefüllt wurden, waren 294 im Hinblick auf die Frage nach einer allfälligen Reanimation auswertbar. Die Fragebögen enthielten neben Fragen betreffend Einstellung der PatientInnen zu medizinischen Maßnahmen und Reanimation auch Fragen, mit denen die physische, psychische und soziale Situation/Befindlichkeit evaluiert wurde.

Ergebnisse: Als Ergebnis zeigte sich, dass 44 % der Befragten eine allfällige Reanimation ablehnten während 56 % keinen Einwand gegen diese Maßnahme äußerten. In beiden Gruppen zeigten sich keine statistisch signifikanten Unterschiede im Hinblick auf die untersuchten Dimensionen psychische Befindlichkeit, physische Befindlichkeit, Hilfsbedürftigkeit bei Körperpflege, Mobilität, Schmerzen, Übelkeit, Dyspnoe und Schwäche. Die Gruppen unterschieden sich ebenfalls nicht in Bezug auf religiöses Bekenntnis, Wohnsituation und Alter.

Schlussfolgerungen: Unsere Ergebnisse zeigen, dass etwas weniger als die Hälfte der Patienten, die auf unserer Palliativstation aufgenommen werden, eine allfällige Reanimation ablehnen. Im Setting unseres Assessments (strukturiertes Interview) konnten kein Einfluss des physischen, psychischen und sozialen Status auf diese Entscheidung festgestellt werden. Mögliche Einflussfaktoren auf das Ergebnis unserer Auswertungen inkludieren unterschiedlicher Befragungsmodus, vorbestehende psychopharmakologische und medizinische Therapie, unterschiedliche Phasen der Krankheitsverarbeitung, unterschiedlicher Wissensstand in Bezug auf die Grunderkrankung, soziale Erwünschtheit und divergente Vorstellungen über Reanimation. Zukünftige Studien sollten diesen möglichen Einflussfaktoren Rechnung tragen. Background: Colony-forming units of endothelial progenitor cells ("CFU-EC") have been introduced as a powerful biological marker for vascular function and cumulative cardiovascular risk. The level of "CFU-EC" has even been described to predict the occurrence of cardiovascular events and death from cardiovascular causes and may identify patients at increased cardiovascular risk. The precise mechanisms underlying "CFU-EC" formation and their cellular composition are unknown.

Methods: We performed detailed subtractive "CFU-EC" analyses in blood samples of 18 healthy volunteers. The impact of various blood cell types and kinetics of protein and gene expression were studied by cell sorting, flow cytometry, quantitative RT-PCR and full genome microarray analyses. "CFU-EC"-derived soluble factors were measured by multiplex cytokine display and functionally tested during endothelial network formation.

Results: "CFU-EC" contained more than 99% CD45 + nucleated hematopoietic cells mainly comprising T cells and monocytes admixed with B and NK cells. Interestingly, purified T-cells plus monocytes were able to form "CFU-EC" clusters. The complete lack of colony formation after depletion of T cells or monocytes was contrasted by an unaffected "CFU-EC" formation after depletion of CD34 + progenitors. Gene expression profiling revealed an activation of various immune function-related biological processes but no changes in pathways assigned to angiogenesis. Soluble factors derived from "CFU-EC" cultures supported the vascular regenerative function of Endothelial Progenitor Cells (EPC) in vitro.

Conclusions: Unravelling "CFU-EC" formation as a result of a functional crosstalk between T cells and monocytes shifts expectations on vascular regenerative medicine. The data support a switch from a sole view on circulating EPC towards models that recognize the contribution of immune cell function during vascular regeneration. Background: Yttrium-90 (Y-90) Ibritumomab Tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody devel-oped for radioimmunotherapeutic targeting of CD20+ lymphoma cells. Using Zevalin, a localised cytotoxic radiation is administered to malignant cells with only minimal side effects on other organs.Methods: 38 patients with relapsed or refractory Non Hodgkin Lymphoma (NHL) were treated in this cohort. 26 patients had relapsed or refractory follicular lymphoma, 8 patients had relapsed or refractory diffuse large B cell lymphoma, 2 patients suffered from Immunocytoma and 1 patient had mantle cell lymphoma. The median age was 63 years. 35 patients were extensively pre-treated with a median of 13 prior therapy cycles (range 3-19). In 3 patients Zevalin was administered as first line therapy. The Zevalin treatment regimen consisted of pre-treatment with Rituximab (250 mg/m^2 intravenously on day 1 and 8) to deplete peripheral blood B cells followed by Zevalin infusion on day 8. A mean of 1067 MBq (range 680-2040) Y-90 Ibritumomab Tiuxetan (Yatrics-Zevalin, Schering AG) was administered. Remission was evaluated 3 month after Zevalin therapy.Results: So far the response to treatment could be evaluated for 33/38 patients. The overall response rate was 76%. 58% (19/33) achieved complete remission/complete remission unconfirmed (CR/CRu), 18% (6/33) achieved partial remission and 24% (6/33) showed no or only minimal response to treatment (5/6 succumb to disease and 1/6 had progressive disease). The response of 5 out of 38 patients is not yet evaluated. 16 out of the 19 CR/CRu are still in CR/CRu with a median duration of response of 16 months (range 5-27). Two patients relapsed and one patient in CR died due to myocardial infarction. The main side effect was thrombocytopenia followed by mild leukocytopenia and anemia. There were no significant affects on other organ function.

Conclusions: Zevalin is an effective and promising therapeutic option especially in elderly and extensively pre-treated patients with CD20+ NHL with only minimal side effects.

Differential CD44 methylation in haematologic malignancies J. D. Rudzki, B. Kircher, A. Amberger, G. Gastl, R. Stauder Immunobiology and Stem Cell Laboratory, Division of Hematology and Oncology, Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria

Background: CD44 comprises a family of class I transmembrane glycoproteins, which exists in several isoforms. This surface molecule has been involved in various processes such as tumorigenesis, haematopoiesis and inflammation. The standard CD44 isoform is expressed on all types of mature blood cells, on the majority of mononuclear bone marrow precursors and on all CD34+ haematopoietic progenitor cells. Changes in expression of CD44 have been shown during the early differentiation of primitive haematopoietic cells as well as in certain aggressive lymphomas. Elevated expression of CD44 has been reported from patients with acute and chronic myeloid leukaemia (AML, CML) or a late form of myelodysplastic syndrome (MDS).

Methylation of CpG sites in the promoter region has been often described as a potent way of restricting gene expression, called "gene silencing". A small part of the total DNA com-prises CpG islands, in which CpG dinucleotides occur at a higher frequency than in the rest of the genome. These regions are normally unmethylated. When methylated, CpG islands in gene-regulatory (promoter) sequences may repress transcription.

Aim: The aim of this study was to gain information about the methylation pattern of CD44 and furthermore to evaluate if alterations in methylation represent a regulatory mechanism of CD44 expression. Methylated regulatory sequences are discussed in diverse malignancies like colorectal or gastric carcinoma but often without any information about the percentage of methylated versus unmethylated CpGs. This implicates the question after a consistent relationship between methylating/demethylating events and expression and needs to be further elucidated.

Methods: Genomic DNA was isolated from three cell line and blood samples from an AML and an MDS patient, converted by bisulfite modification and analysed by methylationspecific polymerase chain reaction. Cloning and subsequent sequencing the amplificates was performed to an analyze the methylation pattern within and at the boundary of exon 1 of CD44, an approximately 700 bp region.

Results: All three cell lines showed a diverse methylation pattern of CD44. The lowest amount of methylation was observed in the CML cell line K-562 (2%). An increased percentage of methylated CpGs was displayed in the AML cell line , whereas the highest CD44 methylation was registered in the lymphoma cell line U-937.

Conclusions: These analyses reveal a differential pattern of CD44 methylation in haematological malignancies, displaying in general a lower percentage of methylation sites as compared to neuroblastoma (100%) or prostate cancer (30-100%). The analysis of the patients' methylation pattern and the corresponding CD44 expression are currently under investigation.

Supported by "Tiroler Verein zur Förderung der Krebsforschung" and "Österreichische Krebshilfe-Krebsgesellschaft Tirol".

Clinical scale expansion of MSC with human platelet lysate K. Schallmoser 1,4 , C. Bartmann 1, 2, 4 

We developed a new model for the FBS-free propagation of human MSC for clinical application. We analyzed the capacity of different preparations of human platelet lysate (HPL) to replace FBS for clinical scale MSC production with cytomic, proteomic and genomic technology.

Results: Using a two-step good manufacturing practice (GMP) procedure for MSC propagation, we found that HPL can fully replace FBS as a growth factor supplement for clinical scale MSC preparation. HPL was reproducibly more efficient than FBS and supported the outgrowth of >400 million MSC from <0.4 million primary MSC (derived from <2mL bone marrow aspiration within 10 days ex vivo) within less than 4 weeks of culture. Although morphologically distinct, HPL-MSC and FBS-MSC did not differ regarding their CD13 + /29 + /73 + /90 + /105 + /146 + /34 -/45 -/133 -/HLA-AB + immunophenotype. Multiplex analyses allowed delineating a distinct cytokine and growth factor profile. Whole transcriptome microarray analyses revealed a differential regulation of >300 genes after only one cycle of human as compared to bovine growth factor stimulation. Allogeneic HPL-MSC infusion in an intent to treat refractory GvHD was feasible and without infusion-related side effects.

Conclusions: This new FBS-free procedure for clinical scale MSC propagation will largely facilitate rational clinical testing of MSC based therapies. Replacing FBS with HPL excludes bovine prion, viral and zoonose contamination of the stem cell product. Based on this protocol a clinical trial for the treatment of steroid-refractory GvHD with HPL-MSC will be initiated. Background: Determination of HER-2/neu expression is routinely performed in primary breast cancer tissue in order to assess the patient's prognosis and the adjuvant treatment plan. The purpose of this study was to examine, whether neoadjuvant chemotherapy influences the HER-2/neu status of breast cancer tissue.

Methods: For 80 patients with breast cancer, treated with neoadjuvant anthracycline-based chemotherapy, the immunohistochemical tissue scores of HER-2/neu were determined in the biopsy samples obtained before initiation of neoadjuvant chemotherapy and in the surgically removed tumors after completion of the neoadjuvant treatment. Membrane immunoreactivity and membrane staining patterns were evaluated using the HercepTest™ with a scoring system of 0 to 3+.

Results: Changes of the HER-2/neu expression scores between biopsy sample and the post-chemotherapy tumor sample have been observed in 32 (40%) patients. In 2 (2.5%) patients HER-2/neu score changed from 0 to 1+, in 19 (23.8%) patients from 1+ to 0, in 2 (2.5%) patients from 1+ to 2+, in 5 (6.3%) patients from 2+ to 0, in 3 (3.8%) patients from 2+ to 3+ and in one (1.3%) patient from 3+ to 0. Case reports: Four patients (3 females, 1 male, age at diagnosis 26-61 years) with severe idiopathic AITP with a late spontaneous remission are described. All had serum antibodies to platelet GP IIb/IIIa, two patients had a lupus anticoagulant (LA). All were refractory to initial steroid therapy, two to SE (two refused SE), one to 3 courses (2-6 months) of low dose azathioprine (20 years prior to remission) and the other one to a 2 months course of cyclosporine (4 years prior to remission). All patients received low dose continuous or intermittent steroids. Six to 31 years after diagnosis these patients achieved a spontaneous CR (n = 3) or partial remission (n = 1) unrelated to any specific second or third line treatment, CR are sustained for 0.5+ to 9+ years. GP IIb/IIIa antibodies disappeared in two patients in haematological remission (but were detectable on platelets in one of them). The LA disappeared in one patient.

Conclusions: Few cases are reported on spontaneous late remission in children after more than 5 years disease duration; only 5 adult patients with severe AITP have been described earlier who failed SE and achieved late spontaneous remissions after 5-12 years. Our data indicate that spontaneous remissions may occur in AITP even after a long duration of the disease in a small number of patients. We estimate that such late spontaneous remissions occur in about 1% of AITP patients.

Poorly differentiated neuroendocrine tumours of non lung origin -a single institution experience Background: Poorly differentiated neuroendocrine tumours (NET) mostly arise in the lung (SCLC) but may also develop in other parts of the body. There are a number of treatment studies in SCLC, but reports on treatment of NET of non lung origin are limited.

Methods: We report our experience in patients with poorly differentiated neuroendocrine tumours of non lung origin who were found in a database that contains more than 10.000 patients with malignancy. 15 patients with poorly differentiated neuroendocrine tumours were collected.

Results: Median age was 55 years (range 45-81). 5 patients had a localized stage, 10 patients presented with advanced stage. Regions of tumour manifestation included liver (n = 4), bone marrow (n = 3), lymph node (n = 3), pancreas (n = 1), larynx (n = 1), stomach (n = 1), esophagus (n = 1), bone (n = 1), cerebrum (n = 1), uterus (n = 1), urine bladder (n = 1) and nose (n = 1). 5 patients with localized stage had local treatment (surgery [n = 4] and/or irradiation [n = 2]) as well as adjuvant chemotherapy (n = 4). 2 of these patients died after 10 and 17 months, 3 patients are still living 4-53 months following diagnosis. 11 patients with advanced disease (10 patients with primary advanced disease and 1 patient with relapse following local treatment) received first line chemotherapy (6 cisplatin based, 5 anthracyclin based chemotherapy). The remission rate achieved was 36.3% (3 PR, 1 CR). The median duration of response was 5 months (4-9) and the median survival 7 (4-27) months.

Conclusions: We confirm that poorly differentiated neuroendocrine tumours of non lung origin are chemosensitive. However the prognosis of advanced stage disease is still poor due to relapse. Some patients with localized disease may achieve long term survival. Background: For the treatment of tumor patients not only the somatic diagnostics, but also the considerations of psychological and social features are of importance. A timely recognising and supporting of those patients with psycho-social burden represents an essential improvement of the quality of life of tumor patients. The aim of the study was the observation of the subjective somatic and psychological burden, as well as the indication for psycho-social care for patients at the oncology-unit at the hospital in Oberwart, Austria, with the help of the questionnaire Psychoonkologische Basisdokumentation (PoBado).

Methods: In connection with the psycho-oncologic first conversation 123 patients were evaluated in the time period between February 2005 and October 2006. The first part of the questionnaire comprises the most important socio-demographic and medical parameters of the patients. The second part comprises somatic burden (4 items) and the psychological burden (8 items). The experiences of the patients were rated on a 5-point Likert scale. Three further items contain possible additional loads. The time window to be judged included the last 3 days before the stationary stay. The evaluation of the data, as well as the comparison with the referencepopulation took place through the PoBado-Projektzentrale at the TU-Munich.

Results: The examined population was to 60% in an advanced disease stage and exhibited in 52 percent additional illnesses. Only 29% of the patients were not under tumor-specific therapy in the last two months. The sum-score of the somatic trouble was 6.2 and this was slightly increased in comparison to the reference-population of 5.5 (n = 4596). In the case of the psychological complaints a sum value of 10 resulted. This corresponded to that of the reference-population (10.2). Incriminating problems in the families and circle of friends emerged in 30.9%, economic and/or vocational problems in 7%. The indication for professional psycho-social support was determined in 61.8% (59.9% in the reference-population).

Conclusions: For the treatment of patients with tumor-illness more frequently also their subjective feeling (in psychological, somatic and social regard) should be considered systematically. This is true for the doctor/patient-relationship, as well as for the indication for accompanied therapy-measures or the evaluation of the new therapies through clinical trials. The up to now used instruments Karnofsky-Index or Spitzer-Index, refer exclusively on physical functional ability. With help of the questionnaire of PoBado we could find a slightly elevated score for somatic trouble and a high need of psychosocial care-demand of 61.8% in our collective. Background: Clinical observations and recent experimental data suggest an anti-angiogenic effect of the proteasome inhibitor bortezomib independent from its anti-tumor activity.

Aim: To assess bortezomib's anti-angiogenic effects in vitro and in vivo and to characterise the exact mechanism of angiogenesis inhibition.

Methods: Human umbilical vein endothelial cells (HUVECs) and circulating endothelial progenitor cells (CEPs) were isolated from umbilical cords and peripheral blood, respectively. All experiments were performed separately for both cell types. Cell viability was determined in WST-1 assays, apoptosis was assessed using DAPI staining, flow cytometry and cell cycle analysis. Tube formation capacity was examined with Matrigel ® assays, cell migration was investigated using standard Boyden chambers. For assessment of anti-angiogenic effects in vivo, Matrigel ® containing VEGF was injected subcutaneously into C57BL mice. Bortezomib (1 mg/kg q72 hours) was administered intraperitoneally. After 14 days mice were sacrificed, Matrigel ® implants were removed and microvessels counted using Isolectin B4.

Results: In subconfluent cell cultures pre-incubation with bortezomib over 24 hours significantly reduced cell viability in a dose-dependent fashion (EC50: 5 ng/ml). Moreover, bortezomib (5-10 ng/ml) induced apoptosis in proliferating HUVECs and CEPs involving the activation of caspase-3. In sublethal doses (e.g., 1 ng/ml), bortezomib exerted a cell cycle arrest in phase G1. In contrast, no apoptosis induction was detectable in confluent endothelial cell cultures even with bortezomib concentrations as high as 10 ng/ml. Tube formation on Matrigel ® and endothelial cell migration were also inhibited significantly in a dose-dependent fashion (1-10 ng/ml). In vitro observations were confirmed in our in vivo model where VEGF-induced sprouting of subcutaneous microvessels into the Matrigel ® matrix was abrogated by systemic administration of bortezomib.

Conclusions: Our study shows that bortezomib displays profound anti-angiogenic properties in vitro and in vivo. This effect is most pronounced in proliferating endothelial cells and involves apoptosis induction via caspase-3.

Quality of response and survival in myeloma patients undergoing conventional chemotherapy K. Strasser-Weippl, H. Ludwig

Background: The relationship between response and survival in multiple myeloma has been discussed in several studies with conflicting outcomes. In particular, it is unclear whether the magnitude of M-protein reduction apart from a complete remission is relevant for patients undergoing conventional chemotherapy.

Methods: We retrospectively analyzed data from a study evaluating continuous versus intermittent prednisone and polychemotherapy with VMCP in 292 myeloma patients. Response was determined according to EBMT criteria and correlated with survival. In addition, we conducted a Medline literature review on studies analyzing the relationship of response and survival in myeloma patients treated with conventional chemotherapy.

Results: In our own cohort, response was significantly associated with survival in 260 evaluable patients (P 8.91 × 10 -8 ). If patients with PD were excluded, only those reaching a CR did significantly better than all other patients (P 0.0425). In a multivariate analysis including response, stage at diagnosis, age, gender and M-protein type, only response, stage and age were prognostically relevant (P-values 6.3 × 10 -6 , 0.014, and 0.0038, respectively). In the literature review, we identified 15 trials published since 1967, including 2252 patients which fit to the criteria described above. The trials showed significant heterogeneity regarding treatment setting, treatment regimens, and length of treatment. The magnitude of paraprotein reduction required for a response ranged from 25% to 75%. In all studies, patients with progressive disease were included in the non-responder category. Overall, 11 of the 17 analyses (2 studies included 2 analyses each) showed a significant relationship between response and survival, while in 5 of the 6 other analyses the association did not reach statistical significance. In one study, the survival of responders was 26.5 months versus 29 months in non-responders (n.s.). A compre-hensive table including trial characteristics and results will be presented.

Conclusions: When response defined by paraprotein reduction is compared to non-response including SD and PD, it is associated with prolonged survival in myeloma patients undergoing conventional chemotherapy. The magnitude of paraprotein reduction required to translate into longer survival remains undefined by the available data. Background: The XPD gene is involved in nucleotide excision repair of DNA by opening the DNA around the damage. It also takes part in the initiation of RNA transcription by RNA polymerase II. The Lys751Gln polymorphism of this gene is suspected to be a predisposing factor for NSCLC development as polymorphic variants of this gene have different repair efficiency. The aim of this study was to establish the frequencies of the polymorphic XPD Lys751Gln genotypes in Polish population and to assess the associated risk of NSCLC development.

Materials and methods: The study group included 162 NSCLC patients (13 females and 149 males) who underwent curative pulmonary resection between the year 1996 and 2000. The control group included 485 healthy subjects. DNA was extracted from frozen blood samples. XPD Lys751Gln polymorphism was evaluated by PCR-RFLP based methods.

Results: The frequencies of XPD gene Lys751Gln genotypes (Lys/Lys, Lys/Gln, Gln/Gln) in NSCLC patients were 38.3%, 43.2% and 18.5%, respectively and 37.1%, 46.2% and 16.7% respectively in healthy controls. The proportion of Gln allele carriers vs Lys homozygotes was insignificantly lower in the NSCLC group than in controls (61.7% vs. 62.9%, p = 0.86).

Conclusions: These results indicate that XPD (gln751 variant) polymorphism does not carry increased risk of NSCLC development. Neutrophil granulocytes are short-lived leukocytes that have to be constantly regenerated from myeloid progenitors. Retinoid-X-receptor-alpha (RXRα) is the predominant RXR protein in myeloid cells. RXRα is able to heterodimerize with other nuclear receptor (NR) family members or form signalcompetent homodimers. RXRα partner availability regulated by intracellular RXRα abundance is thought to determine NR signaling. However its regulation in primary neutrophil versus monocyte differentiation remained uncharacterized. Here we show that myeloid progenitors express RXRα protein at sustained high levels during M-CSF-induced monopoiesis. In sharp contrast, RXRα is downregulated during G-CSF induced late-stage neutrophil differentiation. Ectopic RXRα inhibited G-CSF-dependent cell proliferation of granulocyte progenitors as well as their differentiation to late stage LF+ neutrophils in a serum-free culture model of CD34+ human progenitors. Furthermore, ectopic RXRα was sufficient to redirect G-CSF stimulated progenitors to monocytes. In line with its elevation in monocytes, RXRα failed to inhibit, but rather augmented M-CSF-dependent monocyte generation. Functional genetic interference with RXRα signaling in hematopoietic progenitor/stem cells using a "dominant-negative" RXRα promoted the generation of late stage granulocytes in vivo and in vitro. Therefore, downregulation of RXRα protein is required for neutrophil generation. This differential regulation of RXRα protein expression is determined by granulocyte versus monocyte cytokine signals.

Relative numbers of CD4+ effector memory T-cells negatively predict for reduced treatmentfree survival in B-CLL I. Tinhofer, L. Weiss, G. Rubenzer, C. Holler, R. Greil Laboratory of Immunological and Molecular Cancer Research (LIMCR), 3rd Medical Department of Hematology, Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Private Medical University, Salzburg, Austria Background: As major mechanism of tumor immune escape both the suppression of tumor-controlling immune cells and the outgrowth of cells with tumor-supportive functions has been postulated. In the current study we addressed the question whether an interaction of T-cell subsets with the course of disease exists in B-CLL and whether this could be explained by a selection toward tumor-supportive T-cells within the Tcell compartment of B-CLL patients.

Methods: Flow cytometric analysis was applied to determine relative distribution and absolute numbers of naive (T naive ), central memory (T CM ), effector memory (T EM ) and effector T-cells (T EMRA ) in peripheral blood samples of B-CLL patients (n = 175) and healthy age-and sex-matched controls (n = 67). Relative numbers of T-cell subsets were correlated with treatment-free and overall survival. Functional studies were performed to reveal potential survival signals delivered to B-CLL cells by specific T-cell subsets.

Results: A significant skewing of the CD4+ T-cell pool with a decrease in CD4+ Tnaive (p < .0001) in favor of an increase in T EM (p < .0001) was observed in the CD4+ T-cell pool which was more prominent than in the CD8+ T-cell pool, occurred very early in clinical course and was significantly more pronounced in progressive as compared to stable patients. Univariate analysis identified a relative number of >15% T EM cells within the CD4+ T-cell pool as risk parameter for reduced treatment-free survival (hazard ratio: 2.5, 95% CI 1.2-4.9, p = .01), and it retained significance even when absence/presence of p53 aberrations were included in the multivariate analysis (hazard ratio: 2.7, 95% CI 1.1-6.3, p = .01). Interleukin-4 could be identified as potential mediator of CD4+ T-cell-induced survival of B-CLL cells in vitro.

Conclusions: We could demonstrate a significant influence of CD4+ T EM cells on the course of disease in B-CLL. Functional studies in the future are required to elucidate the exact molecular mechanisms of this interaction.

Fallbericht: 51/2 Jahre, anhaltende, komplette Remission eines metastasierten gastrointestinalen Stromatumors unter Glivec ® E. Ulsperger 1,3 , E. Gaisfuss 2 , P. Bratusch-Marrain 2 , K. Geissler 1,3 1 5. Medizinische Abteilung, Onkologie, Krankenhaus Hietzing, Wien, Österreich; 2 Interne Abteilung, Waldviertel-Klinikum Horn, Horn, Österreich; 3 Ludwig Boltzmann Institut für klinische Onkologie Lainz, Wien, Österreich Grundlagen: Gastrointestinale Stromatumore (GIST) zählen zu den Spindelzelltumoren und unterscheiden sich von Leiomyomen und Schwannomen durch die Expression von CD117 (c-kit). Seit nunmehr 6 Jahren steht für GISTs mit dem Tyrosin-kinase-Inhibitor Glivec ® , eine spezifische Therapie zur Verfügung.

Methodik (Fallbericht): Ein 62-jähriger Mann wurde im August 2001 mit den Symptomen einer Harnverhaltung mit Restharn, Nephropathie, Diabetes mellitus (insulinpflichtig seit 1981), und 20 kg Gewichtsverlust stationär aufgenommen. Klinisch wurde eine massive Lebervergrößerung (5 Querfinger) mit entsprechend erhöhten Leberparametern und eine große tumoröse abdominale Raumforderung -einem Darmkonvolut entsprechend -gefunden. In der Computertomographie (CT) fanden sich den gesamten peritonealen Raum ausfüllende Auflagerungen, großteils die Darmschlingen umscheidend sowie hypodense Leberherde (2 cm groß). In einer U-Schall-gezielten Biopsie konnte ein c-kit positiver Spindelzelltumor, einem GIST entsprechend, nachgewiesen werden.

Ergebnisse: Aufgrund des bekannt schlechten Ansprechens auf zytostatische Therapie leiteten wir ambulant eine Therapie mit Glivec ® (400 mg täglich) ein. Bereits nach den ersten vier Wochen zeigte sich klinisch sowohl eine deutliche Verbesserung des Allgemeinzustandes als auch eine Tumorreduktion. Nach dem 2. Monat dieser Therapie konnte die klini-sche Besserung in der CT-Kontrolle verifiziert werden (50 % Rückgang). Diese Entwicklung setzte sich im Laufe der weiteren Therapie fort und in weiterer Folge zeigte die CT eine fast komplette Remission. Parallel dazu kam es zu einer Normalisierung der Leberparameter. Als Nebenwirkungen wurden von dem Patienten anfänglich leichte Lidödeme und Knöchelödeme bemerkt. Diese besserten sich trotz Fortsetzung der Glivec ® -Therapie ohne Dosisreduktion. Nach 18 Monaten Therapie kam es einmalig zu einer gastralen Ulkusblutung, die transfusionsbedürftig war. Eine "second look" Operation lehnt der Patient bis dato ab. Der Patient ist im sechsten Jahr der Therapie, mit 400 mg Glivec ® täglich, beschwerdefrei.

Schlussfolgerungen: Die Fortsetzung der Therapie in unveränderter Dosis ist geplant.

Dickkopf-homolog-3 is required for vasculogenesis and is overexpressed in tumor vessels of aggressive human gliomas G. Untergasser 1 , M. Zimmermann 1 , J. Kern 1 , H. Rumpold 2 , M. Hermann 3 , G. Gastl 1 , E. Gunsilius 1 Background: Vascular endothelial growth factor (VEGF) is produced in neoplastic cells in various myeloid malignancies including acute and chronic myeloid leukemias. VEGF is considered to play an important pathogenetic role as a mediator of leukemia-associated angiogenesis. In addition, VEGF has been described to directly stimulate leukemia cell growth through specific receptors and thus may act as an autocrine growth regulator. However, although various receptors for VEGF have been identified, little is known about expression and distribution of these receptors on neoplastic cells in the various myeloid leukemias.

Methods: In the present study, we have examined expression of VEGF and of five different VEGF receptors (Flt-1, Flk-1/KDR, Flt-4, neuropilin-1 = NRP-1, neuropilin-2 = NRP-2) in neoplastic myeloid cells including cell lines (HL60, U937, KG1, KG1a, K562, KU812, EOL-1, HMC-1) as well as primary neoplastic cells obtained from 28 patients with acute myeloid leukemia (AML), 14 with chronic myeloid leukemia (CML), 9 with chronic myelomonocytic leukemia (CMML), 3 with chronic eosinophilic leukemia (CEL), and 3 patients with mast cell leukemia (MCL, n = 1) or systemic mastocytosis (SM, n = 2). Expression of VEGF-and VEGF receptor mRNA was analyzed by RT-PCR and expression of the VEGF protein by immunocytochemistry.

Results: Confirming previous data, VEGF mRNA and the VEGF protein were detectable in most patients and most cell lines examined. In all patients and all cell lines tested, neoplastic cells were found to express transcripts for NRP-1. In addition, neoplastic cells also co-expressed NRP-2 in most cases. By contrast, transcripts for Flt-1, KDR, and Flt-4 were expressed variably in leukemic cells. In some cases, a correlation between VEGR expression and the type of leukemia was found. Likewise, in AML, KDR mRNA was found to be expressed primarily in blast cells in patients with FAB M4 (7/9; 78%) and M7 (2/2). Transcripts for KDR were also detected in 2/3 patients with mast cell disease, but were not detected in patients with CEL. Interestingly, Flt-1 mRNA levels were found in the patient with MCL and in the MCL cell line HMC-1, but neither in patients with SM or CEL nor in the CEL-related cell line EOL-1. Another interesting observation was that Flt-4 mRNA was expressed in neoplastic monocytes in a majority of all CMML patients examined (7/9; 78%). Flt-1, KDR, and Flt-4 were found to be expressed variably in the myeloid cell lines examined without a clear correlation to the type of leukemia.

Conclusions: VEGF receptors including the co-receptors NRP-1 and NRP-2, are frequently expressed in neoplastic cells in various myeloid neoplasms including AML, CML, CMML, CEL, and MCL. The notion that these neoplastic cells express and secrete VEGF in a constitutive manner and can express additional VEGFR favors the hypothesis that VEGF may act as autocrine growth regulator in some of these malignancies.

Palonosetron -cost-effective prevention of chemotherapy-induced nausea and vomiting (CINV) E. Walter 1 , S. Zehetmayr 1 , G. Achzet 2 1 IPF Institute for Pharmaeconomic Research, Vienna, Austria; 2 CSC Pharmaceuticals Handels GmbH, Bisamberg, Austria

Background: Despite ongoing improvements in supportive cancer therapy, nausea and vomiting are among the most inconvenient adverse events experienced by cancer patients treated with cytotoxic chemotherapy. Various antiemetic drugs are available for prevention of chemotherapy-induced nausea and vomiting (CINV). While conventional 5HT 3 -receptor antagonists obviously represent a major milestone in the management of acute CINV, prevention of delayed nausea and vomiting on days 2-5 requires repeat dosing. Palonosetron, a novel 5HT 3 -receptor antagonist, has both a longer plasma halflife and a higher binding affinity. With a single IV dose of 0.25 mg, Palonosetron provides an optimal prevention of acute nausea and vomiting and an improved efficacy in the delayed phase. The objective of this pharmacoeconomic analysis was to economically assess two antiemetic treatment options: palonosetron (0.25 mg IV d1) versus ondansetron (8 mg IV plus 8 mg PO d1 + 2 × 8 mg PO d2-5).

Methods: This comparative economic evaluation of palonosetron versus ondansetron was made using a decision model: the direct medical costs (including medication costs and the cost of medical care provided by doctors in private practice, hospital outpatient clinics and inpatient hospital care) and the effectiveness (complete response (CR) after 0-120 hours) of the two treatment options were captured and modeled for the 5-day observation period of interest. Cost-effectiveness analyses were performed from the perspectives of the health care system, hospitals, and statutory health insurance funds.

Results: From the health care system's perspective, the cost per successfully treated patient for the 5-day observation period was 542.14 EUR for palonosetron. The cost of ondansetron use over the same period was 786.23 EUR. From the perspective of the health care system, the cost-effectiveness benefit from palonosetron use was 244.09 EUR. From the hospitals' perspective, the costs of palonosetron and ondansetron use per successfully treated patient during the 5-day (treatment) period were 531.44 EUR and 594.38 EUR, respectively. The cost-effectiveness benefit conferred by palonosetron versus ondansetron was 62.94 EUR. From the perspective of statutory health insurance funds, the cost per successfully treated patient was 10.72 EUR for palonosetron versus 191.85 EUR for ondansetron. The cost-effectiveness benefit from palonosetron use was 181.14 EUR.

Conclusions: Antiemetic supportive care of cancer patients using palonosetron was more cost-effective than treatment with ondansetron from each stakeholder's perspective. Background: Capecitabine, an oral fluoropyrimidine recently approved for the treatment of metastatic colon and breast cancer, is currently under investigation in patients with gastric cancer. The following dermatologic reactions associated with the use of capecitabine have been previously reported: palmar-plantar erythrodysesthesia, photoeruption, "dermatitis", leopardlike vitiligo, "erythematous rash", onycholysis, pyogenic granulomas, radiation recall, and xerosis.

Methods: A 77-year old woman presented at the Department of Dermatology with a three-week history of erythematosquamous plaques. The patient had been treated with capecitabine for advanced gastric cancer. Seven days after initiation of capecitabine monotherapy, erythematosquamous skin lesions on the face, neck, anterior parts of the upper trunk, the lower arms, the dorsum of the hands and dorsal surfaces of her fingers developed. The patient also noticed increased photosensitivity. Myalgias, arthralgias, or fever were not noted. Previous medical history was otherwise unremarkable.

Results: Laboratory results (anti-Ro antibodies) and histology were consistent with the diagnosis of subacute cutaneous lupus erythematosus (SCLE). Treatment with topical steroids and sun protective measures were initiated and after discontinuation of capecitabine treatment, cutaneous lesions completely resolved within 6 weeks and no further SCLE flares were observed.

Conclusions: Lupus erythematosus and lupus-like drug eruptions have been observed after 5-fluorouracil treatment, but so far have not been described in patients treated with capecitabine. As capecitabine is being used increasingly in the treatment of breast and gastrointestinal cancers, clinicians should be aware of this important novel cutaneous adverse reaction.

Development of pemphigus vulgaris after fludarabine treatment despite simultaneous administration of rituximab and cyclophosphamide A. Weimar 1 , R. Feldmann 2 , K. Geissler 1,3 1 5 th Medical Department-Oncology, 2 Department of Dermatology, Hospital Hietzing, Vienna, Austria; 3 Ludwig Boltzmann Institute of Clinical Oncology, Vienna, Austria Background: Chronic lymphocytic leukemia (CLL) is a hematological malignancy which may be associated with autoimmune disease such as autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenia (ITP). Fludarabine is a cytotoxic agent which is increasingly used in the treatment of CLL alone or in combination with other drugs. Increased incidence of AHIA and ITP during fludarabine therapy has been observed. 3 cases of paraneoplastic pemphigus in adult men with CLL have also been reported after fludarabine treatment (C. Gooptu et al, Br J Dermatol 2001) . Rituximab and cyclophosphamide on the other hand have been shown to be effective in some autoimmune diseases. In particular treatment of rituximab and Ig has been shown to be effective in patients with refractory pemphigus vulgaris (R. Ahmed et al, NEJM 2006) .

Methods: We report a patient with CLL, who developed severe pemphigus vulgaris after treatment with a immunochemotherapy consisting of rituximab (R), fludarabine (F) and cyclophosphamide (C).

Results: In July 2006 a 60 years old male patient was diagnosed as CLL by histological investigation of a cervical lymph node. WBC was slightly increased (10300/mcl) with 51% lymphocytes and the demonstration of a CD5 coexpressing CD19 positive B-cell clone. Because of B-symptoms, a rapidly progressing lymphadenopathy and the presence of an adverse cytogenetic aberration (11q deletion by FISH) the patient was treated in November with the first R-FC treatment. 2 weeks after chemotherapy the patient presented with bilateral conjunctivitis, blistering exanthema and stomatitis. During the next days exanthema and stomatitis became worse and the patient had to be admitted to the hospital in order to supply parenteral fluid and nutrition. Because of expanding blistering eruption with mucosal involvement pemphigus vulgaris was suspected. A skin biopsy was performed and serum was tested for antibodies against desmoglein. Diagnosis of pemphigus vulgaris was confirmed by the demonstration of epidermal acantholysis and keratinocyte necrosis, by immunofluorescence revealing typical binding of both IgG and C3 in a focal, intercellular epidermal pattern and linear granular pattern at the basement membrane, by immunoprecipitation and immunoblotting demonstrating several characteristic target antigens of molecular weights 250kD, 210 kD, 190 kD and 130 kD and the detection of antibodies against desmoglein 1 and 3 by a sensitive enzyme-linked immunosorbent assay. Shortly after administering high dose corticosteroids exanthema and mucosal changes significantly improved. At the moment the patient is receiving corticosteroid maintenance therapy.

Conclusions: Since rituximab and cyclophosphamide have been shown to be effective in the treatment of pemphigus vulgaris and an association between fludarabine and pemphigus vulgaris has been observed it is likely that fludarabine may be the causative agent in the development of pemphigus vulgaris in this patient. It is of particular interest that the administration of rituximab and cyclophosphamide given simultaneously with fludarabine was apparently not effective in protecting the patient from this rare but serious complication.

Longitudinal assessment of clinical changes in treatment and outcome of myeloma in Austria; the LACCITO project W. Willenbacher 1 , U. Siebert 2, G. Lackinger 1 , E. Willenbacher 1 , G. Gastl 1

Methods: Microarrays of normal tissue (33 samples) and gliomas (30 samples, 2 cores, gradings II, III and IV) were cultures (CEC, n = 5). Results: In comparison to normal tissue and grade II glirecombinant Dkk-3, adenoviral overexpression or siRNA-mediated downregulation of Dkk-3. Conclusions: Based on our observations

Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and neuropilin-2 (NRP-2)

JAK2 V617F was quantified by correlation with GAPDH. Results: Corresponding results with both assays were achieved in 34 negative patients (15 ET, 4 MF, 1 PV, 14 non-CMPD) and 76 positive patients (25 ET, 5 MF, 45 PV, 1 unclassified CMPD)

RARS-T, 1 unclassified CMPD) weakly positive in qualita

73%) patients with ET, 6/10 (60%) with MF and 46/47 (98%) with PV were JAK2 V617F positive. Conclusions: The quantitative real-time PCR is more sen

Pammer 2 , R. Kristoferisch 2 , C. Drach 3 , F. Keil 1 1 Department für Hämato-Onkologie

In weiterer Folge wurde der Patient in nach kompletter Remission des MZL und bei nunmehr minimaler Restpositivität in der Immunfixation -Ig quant in der Norm, keine Osteolysen -einer konsolidierenden Stammzell-Transplantation unterzogen und ist nun seit 7 Monaten in kompletter Remission. Schlussfolgerungen: Die simultane Erkrankung eines Patienten mit einem MZL und MM ist nach unserem Wissen noch nicht publiziert. Dieser Patient erhielt mit R-CHOP und Thalidomid

Background: Clinical practice does not always adhere to approved indications and accepted treatment guidelines or recommended schedules and regimes. Reasons therefore may be avoidance of expensive drugs, off-label use of registered drugs or treatment modifications due to comorbidities and toxicities. Moreover, expectations on the efficacy and tolerability of novel drugs based on published results from well-controlled clinical trials do not always stand the test of "real life oncology". Concerning drug safety, pivotal approval studies are notoriously underreporting rare toxicities and missing longterm sequelae. To investigate such important issues is a principal duty of the oncological community and can be properly evaluated by representative population-based surveys. Aiming this we have taken multiple myleoma as a paradigm malignancy and developed an internet-based IT infrastructure for a national myeloma survey (LACCITO). Besides providing a comprehensive view on the actual use of myeloma treatments, such a surveillance programme will provide an instrument for quality assessment of cancer care on a national level, generating benchmark values amenable to all participants and health care providers.Methods: Data will be collected cross-sectionally for all Austrian myeloma patients receiving any treatment in the 4th quarter of 2006 (retrospective T 0) and the 1st quarter of 2007 (retrospective T 1). 6 months onward (T 2) from T 1 an outcome inquiry on all pts. identified at T0 and T1 will be entertained, as well documentation of all new treatment decisions and additionally identified pts. At 12 months a second reappraisal on the whole cohort will be performed. Data will be analyzed using standard descriptive statistics and Kaplan-Maier estimates for disease outcome. Austrian hospitals and practicing hemato-oncologists will be invited to take part in LACCITO. This survey will be performed under the auspices of the OEGHO. The documentation form will be offered as a brief questionnaire on paper as well as by an internet-based data record form. A prototype registry developed at the Medical University of Innsbruck including myeloma therapies, risk factors, adverse events, response and survival data as well as basic health economic variables will be used for data collection. If requested participating centers and oncologists will receive support by a registry assistant for data extraction from source data files.Results and conclusions: The LACCITO project represents a cross-sectional survey designed to generate a "real time" report on the current therapeutic management of multiple myeloma in Austria. The data base will be further exploited for health economical analysis and health technology assessment (HTA). Methods: We report on 10 patients with mild to marked unexplained cytopenia without definitive signs of a myeloid neoplasm or criteria for an MDS. Cytopenia was observed for at least 6 months and was not attributable to any other underlying disease.Results: In one patient a thorough re-examination of the bone marrow revealed more than 10% dysplastic bone marrow cells, so that the diagnosis MDS could be established. In two patients, a karyotype-abormality (trisomy 14; monosomy 7) was detected in a small subset of bone marrow cells. Progression to overt MDS was seen in two of the ten patients, including the one with monosomy 7 in whom an increase in blast cells (8%) was found. In the remaining cases, no MDS developed in the follow-up. These patients were classified as 'idiopathic cytopenia of undetermined significance (ICUS)', a term that has recently been proposed by Mufti and others.Conclusions: We recommend to use this term in all patients with unexplained cytopenia in whom minimal criteria for MDS are not met and no other underlying diseases, that could cause cytopenia, are detected. In addition, we recommend a long term follow-up in order to document or exlcude a prephase of MDS. Background: About 2-3% of all colorectal cancers occur in the context of the autosomal dominantly inherited Hereditary Nonpolyposis Colorectal Cancer (HNPCC Lynch syndrome), which is due to mutations in mismatch repair genes. It is of vital clinical importance to diagnose index patients with cancer potentially due to Lynch syndrome. Genetic councelling and testing should be offered to family members. Given certain genetic predispositions, life-long preventative care would be indicated, especially, at focus on colorectal carcinomas, but also with a view for detecting other localizations (endometrium, urothelium, ovaries) . The problems associated with the diagnosis of HNPCC are to be demonstrated on the basis of one of the world's largest documented HNPCC-family, including 51 members over 4 generations.Methods: Because of clinical suspicion for HNPCC, the index patient was analyzed for mutations in MLH1 and MSH2 by direct sequence analysis. A causal mutation (+1343 A>del) was detected in exon 12 of MLH1 gene. Concordantly, putative carriers of this mutation were genotyped.Results: 10 family members carrying the mutation were found, four of them developed a colorectal carcinoma , one of them 3-fold metachronic. Moreover, particularly striking is the age of the person diagnosed (39 years), under controlled circumstances, with an early-stage tumor localized in the coecum and one person who deceased very young (28 years with a sigmoid tumor). There are indications of anticipation in successive generations. The variety of HNPCC tumors is also displayed in the cases of two family members, who had a carcinoma of the stomach, duodenum and endometrium.Conclusions: The primary HNPCC diagnosis by clinical recognition and genetic testing of the index patient plays an essential role in the early detection of these tumors within a preventative care program.